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In this thesis work, the role of astrocyte activation in glioblastoma progression was 
investigated.  Brain tumors contribute to hundreds of thousands of deaths every year.  
Typical survival times for brain cancer patients, even with surgical, chemotherapy, and 
radiation treatment, remain very low despite advances in treatment.  In brain cancers, 
astrocytes, which comprise approximately 50% of the cells in the brain, become activated, 
resulting in a layer of reactive astrocytes surrounding the tumor.  This process of reactive 
gliosis, which involves the secretion of growth factors and cytokines, helps repair injury in 
the brain, but we hypothesize it also plays a role in cancer progression.  In this work, 
methods for culturing quiescent (non-reactive) astrocytes were developed, in order to be 
able to observe the process of activation.  Astrocytes were cocultured with glioblastoma 
cells to investigate their effect on glioblastoma proliferation, invasion, and adhesion, and 
therapies to reduce astrocyte activation were assayed for their ability to slow tumor 
progression.  It was found that a 3D hydrogel consisting of collagen, hyaluronic acid, and 
Matrigel best supported physiological astrocyte morphology and activation, and that 
treatment with astrocyte activation attenuating drugs Ibudilast and Laquinimod are capable 
of reducing glioblastoma invasion in vitro.  In addition, preliminary mouse work indicates 
that treatment with Ibudilast is capable of attenuating astrocyte activation in response to 
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Chapter 1: Introduction 
Astrocyte Background: 
 Astrocytes, the most prevalent type of glial cell in the brain, have traditionally been 
considered only supporting cells for neural function [1].  In recent years, however, 
astrocytes have been found to participate in many diverse brain functions, from regulating 
brain microcirculation to maintaining and repairing the blood-brain barrier (BBB) [2].  
Human astrocytes are usually characterized by a small cell body with numerous radial 
processes resulting in an overall diameter of about 150 µm [3].  Astrocyte end-feet make 
contact with neurons and blood vessels, completely covering the surface of brain capillaries 
[4].  Astrocytes are known to be an essential component of the blood-brain barrier, 
participating in BBB repair and maintenance, producing proteins, such as GDNF and 
bFGF, that enhance BBB tightness, and regulating water, ion, and amino acid homeostasis 
[4].  Astrocytes have also been found to be involved in neurogenesis in the subventricular 
zone, as SVZ astrocytes can differentiate into mature astrocytes, oligodendrocytes, or 
neurons [5]. 
 
Role in the Blood-Brain Barrier 
 Astrocytes interact with microvascular endothelial cells through the end-feet of the 
protrusions that wrap around the capillary [4, 6] (Figure 1).  Brain capillaries are often 
completely surrounded by astrocytic end-feet and one astrocyte may contact multiple 
capillaries [7]. Astrocytes upregulate many features of the blood-brain barrier, including 
tight junction formation, the expression and polarization of transporters, and specialized 
enzyme systems [4, 6, 8-11].  Several astrocyte derived factors, including transforming 
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growth factor-β (TGF-β), glial-derived neurotrophic factor (GDNF), basic fibroblast 
growth factor (BFGF), and angiopoetin-1 (ANG-1) are known to induce blood-brain 
barrier characteristics in endothelial cells [4, 10]. 
 
Figure 1: Configuration of cells in the blood-brain barrier.  Endothelial cells (red) form intra- and 
intercellular tight junctions, and are surrounded by a basement membrane (yellow) made primarily of laminin 
and collagen IV.  Pericytes (green) are contractile cells that wrap around capillaries.  Astrocytes (blue) 
express endfoot processes that completely cover the surface of brain capillaries in the human brain. 
Astrocyte Activation 
 In response to brain injury, stroke, blood-brain barrier damage and cancer, as well as 
several other CNS injuries, astrocytes undergo reactive gliosis, a process that involves the 
upregulation of the intermediate filament proteins GFAP and vimentin, as well as many 
growth factors, inflammatory cytokines, and extracellular matrix proteins [12, 13].  This 
process often helps to repair damage in the injured brain [13], but has been implicated glial 
scar formation and inhibiting axonal regeneration after injury [14], in addition to secreting 
factors implicated in facilitating the growth and spread of cancer [15].  While astrocytes 
are typically in an inactive, quiescent state in vivo, they tend to be very reactive in cell 
culture most in vitro models [3].  Reactive astrocytes have been found to have remarkably 
different gene and protein expression profiles from quiescent astrocytes [12, 13].  In 
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addition to the upregulation of intermediate filament proteins GFAP and vimentin, several 
growth factors, ECM proteins, and inflammatory cytokines, as well as a variety of other 
genes are upregulated in the presence of brain injury [12].  These changes in gene and 
protein expression have been observed to span typically 3-7 days [12, 16] and up to three 
weeks [17] post-injury.   
 
Astrocytes in In Vitro Studies 
 Typical in vitro studies of astrocytes often involve the use of either rodent astrocytes 
[18-21] or commercially available human astrocyte cell lines [22-24].  However, neither of 
these cell types can fully represent physiological human astrocytes in in vitro studies, as 
the commercially available cell lines lack physiological human astrocyte morphology and 
gene expression, and rodent astrocytes tend to be much smaller and expressing fewer 
processes and endfeet than human astrocytes [7, 25, 26].  Astrocytes used in in vitro models 
also typically express markers of activation [18, 19, 27] including high levels of GFAP 
expression, which is often used as a marker for astrocytes in vitro, despite the low levels 
of GFAP expressed by quiescent astrocytes [3].  
 
Glioblastoma and Brain Metastatic Cancer 
 In 2010, approximately 140,000 people in the United States were living with a 
malignant brain tumor [28].  The median survival time for malignant gliomas, which 
account for 80% of all malignant tumors, is approximately 15 months, a figure which has 
remained stagnant over the last 40 years [28].  Treatment for malignant gliomas typically 
involves surgical resection followed by chemotherapy or radiation therapy.  Even with 
4 
 
treatment, however, less than 10% of patients survive five years after diagnosis [29].  In 
addition to primary brain cancers, each year there are approximately 200,000 cases of 
metastatic brain tumors in the US, most of which originate from lung cancers, breast 
cancers, and melanoma [30, 31].  24 - 45% of all cancers result in brain metastases, and 
20% of all yearly cancer deaths result from brain metastases [32]. 
 One of the reasons that tumors in the brain are particularly difficult to treat is that the 
supporting cells of the brain facilitate cancer proliferation and invasiveness [15, 33, 34].  
Microglia, which account for 10 - 15% of the cells in the brain, are known to promote 
glioma invasion and growth, and the presence of microglia in a tumor is associated with 
higher grade tumors and poorer prognosis [33, 34].   While the effect of microglia on cancer 
progression has been well documented [35], the effect of astrocytes, which comprise 
approximately 50% of the cells in the brain, has received much less attention.  Many of the 
growth factors and inflammatory cytokines expressed by microglia that promote cancer 
growth [33, 34] are also expressed by astrocytes [12, 13], complicating the picture of the 
interactions of glial cells with tumors.  In addition, glioma cells themselves, but often not 
brain metastatic cancer cells, also secrete several of these growth factors and inflammatory 
cytokines (Table 1).   
Table 1: Summary of factors secreted by astrocytes, microglia, and glioma cells that promote brain cancer progression 
through proliferation enhancement, invasion enhancement, and immune protection. 
Factor Cells Expressing Enhancement References 
IL-6 Astrocytes, Microglia, Glioma Proliferation, Invasion [8,21] 
IL-10 Astrocytes, Microglia, Glioma Immune Protection [7,11] 
STAT3 Astrocytes, Microglia, Glioma Proliferation, Invasion, Immune Protection [8,11] 
MT1-MMP Astrocytes, Microglia Invasion [7,13] 
TGF-B Astrocytes, Microglia, Glioma Proliferation [7,25] 
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GDF-15 Astrocytes, Glioma Proliferation, Immune Protection [11,24] 
IGF-1 Astrocytes Proliferation [25] 
bFGF Astrocytes, Microglia, Glioma Proliferation [8,20] 
EGF Astrocytes, Microglia, Glioma Proliferation [7,26] 
PDGF Astrocytes, Glioma Proliferation [26,50] 
IL-23 Astrocytes Invasion [31] 
Versican Astrocytes, Glioma Proliferation, Invasion [11,51] 
MMP9 Astrocytes, Microglia, Glioma Invasion [7,30] 
tenascin-C Astrocytes, Glioma Immune Protection [10,45] 
 
 
Astrocyte Contribution to Tumor Progression 
 Astrocytes have been found to influence cancers in several distinct ways (Figure 2).  In 
this section, we address the enhancement by astrocytes on the proliferation and invasion of 
cancer cells, as well as astrocyte protection of tumors from chemotherapeutic-mediated 
apoptosis.  Additionally we address the evidence indicating that astrocytes secrete factors 




Figure 2: Astrocytes modulate cancer progression through: proliferation enhancement, invasion enhancement, 
chemoprotection, and immune protection. In proliferation enhancement, astrocytes secrete several factors, including IL-
6, STAT3, TGF-B, GDF-15, IGF-1, bFGF, EGF, PDGF, and versican.  In invasion enhancement, MMPs are typically 
upregulated or cleaved from inactive forms to active forms, which then degrade basement membrane collagen IV.  Factors 
involved in this pathway include IL-6, STAT3, IL-23, and MT1-MMP.  Chemoprotection involves astrocytes 
sequestering calcium, which prevents chemotherapeutic-induced cancer cell apoptosis.  Immune protection occurs 
through a variety of mechanisms, including downregulating proinflammatory cytokine release to prevent cancer cells 
from being recognized by the immune system (STAT3) and inhibiting immune cell activation or proliferation (tenascin-
C, IL-10).  
Proliferation 
 One of the ways in which astrocytes influence tumors in the brain is by secreting growth 
factors that upregulate tumor cell proliferation.  Several in vitro studies with different cell 
lines have shown increased cell proliferation in the presence of astrocytes, astrocyte 
conditioned media, or factors secreted by activated astrocytes (Table 2).  In one of the earliest 
studies, rat astrocyte metabolic activity was stimulated with phytohemagglutinin and the 
conditioned medium incubated with brain metastatic breast cancer MDA-MB-435Br cells 
for 18 hours.  Tumor cell proliferation increased 400% with conditioned media as 
compared to basal media alone.  To identify the factors causing this dramatic increase in 
proliferation, the effects of IL-6, TGF-β, and IGF-1, which are known to be secreted by 
reactive astrocytes, were examined.  At the concentrations tested (5 U/mL IL-6, 2 ng/mL 
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TGF-β, and 25 ng/mL IGF-1), each growth factor independently resulted in an increase in 
proliferation of 50% over controls [21].   A separate study confirmed that IL-6 also 
promoted the growth of human glioma cells by 25% [36].  IL-6 has been found to promote 
proliferation in several different cancers via the JAK-STAT pathway [18, 37].  In addition, 
GDF-15, a member of the TGF-β family upregulated 12.2x in reactive astrocytes [12], was 
found to result in a 25% increase in proliferation in the human glioma cell line SMA-560 
[38].  A study of the effects of astrocytes on the brain-metastatic lung cancer line HARA-
B determined that unstimulated astrocyte conditioned media had no effect on cell 
proliferation, while incubation with media conditioned by cancer cell-astrocyte co-culture, 
or direct co-culture of cancer cells with astrocytes both increased cancer cell proliferation 
by 150-300% [39].  Additional factors known to be secreted by astrocytes that stimulate 
cancer cell proliferation are bFGF [13] and EGF [40], which have been shown to increase 
the growth of human glioma U-251MG spheroids by 25% and 100%, respectively [41]. 
Table 2: Summary of astrocyte enhancement of tumor growth, invasion, and chemoprotection. ACM – astrocyte 
conditioned media, HSPG – heparin sulfate proteoglycan. 
Cell Type 
Cancer 
Type Condition Assay Effect Ref 
Proliferation 
MDA-MB-435-Br1 Breast ACM 3H Thymidine Uptake 5x proliferation [21] 
MDA-MB-435-Br1 Breast IL-6 5 U/mL 3H Thymidine Uptake 1.5x proliferation [21] 
MDA-MB-435-Br1 Breast TGFB 2 ng/mL 3H Thymidine Uptake 1.5x proliferation [21] 
MDA-MB-435-Br1 Breast IGF1 25 ng/mL 3H Thymidine Uptake 1.5x proliferation [21] 
SMA-560 Brain GDF-15 knockdown+ 5 ng/mL 3H Thymidine Uptake 1.25x proliferation [38] 
U87MG Brain IL-6 100 ng/mL CCK-8 assay 1.25x proliferation [36] 
HARA-B Lung 1:5 coculture w/ astrocytes cell counting 3x proliferation [39] 
HARA-B Lung 1:10 coculture w/ astrocytes cell counting 4x proliferation [39] 
HARA-B Lung ACM cell counting no increase [39] 
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HARA-B Lung HARA-B/Astrocyte CM cell counting 2.5x proliferation [39] 
MDA-MB-231BR Breast Coculture w/ astrocytes 
agar colonization 
assay 4x proliferation [42] 
U-251MG Brain 50 ng/mL EGF spheroid outgrowth 2x proliferation [41] 




Type Condition Assay Effect Ref 
70W Melanoma ACM 
Invasion through 
HSPGs 2.5x invasion [43] 
B16B15b Melanoma ACM 
Invasion through 
HSPGs 2.5x invasion [43] 
H2030 Lung ACM 
Invasion through 
Matrigel 
0 to 120 migrating 
cells [44] 
MDA-MB-231BR Breast ACM 
Invasion through 
Matrigel 
0 to 200 migrating 
cells [44] 
CD133+ NSCII Brain ACM Transwell Migration 3x invasion [40] 
CD133+ NSCII Brain astrocyte co-culture Transwell Migration 3x invasion [40] 
CD133+ GBAM1 Brain ACM Transwell Migration 2.5x invasion [40] 
CD133+ GBAM1 Brain astrocyte co-culture Transwell Migration 3x invasion [40] 
YDFR.CB3 Melanoma astrocyte co-culture 
Transendothelial 
migration 3x invasion [45] 
YDFR.CB3 Melanoma 10 ng/mL IL-23 
Transendothelial 
migration 2x invasion [45] 
MCF-7 Breast astrocyte indirect co-culture Transwell Migration 2x invasion [46] 
U251N Brain astrocyte direct co-culture Transwell Migration 2.5x invasion [47] 
U87MG Brain 100 ng/mL IL-6 
Invasion through 
Matrigel 4x invasion [36] 
MDA-MB-231BR Breast Co-culture w/ astrocytes 
agar colonization 




Type Chemotherapeutic Assay Effect Ref 






 In addition to promoting tumor cell proliferation, astrocytes have also been found to 
directly influence invasion in vitro of primary brain tumor cells [40, 47], melanoma cells 
[43, 45], breast cancer cells [42, 44, 46], and small cell lung cancer cells [44] (Table 2).  
Direct coculture of astrocytes with U251 brain cancer cells increased invasion by 150% in 
a Boyden chamber assay as compared to tumor cells alone.  This effect was completely 
diminished by the addition of the plasmin inhibitor α2 antiplasmin [47].  This same study 
also observed the cleavage of inactive pro-MMP2 to active MMP2 in the presence of 
astrocytes, which is known to be involved in enhanced tumor invasiveness [47].  MMP2 is 
PC14Br4 Lung Taxol AI 0.6x apoptosis [48] 
PC14Br4 Lung Vinblastine AI 0.4x apoptosis [48] 
PC14Br4 Lung Vincristine AI 0.3x apoptosis [48] 
PC14Br4 Lung 5-FU AI 0.4x apoptosis [48] 
PC14Br4 Lung Cisplatinum AI 0.3x apoptosis [48] 
MDA-MB-231 Breast 5 ng/mL taxol AI 0.6x apoptosis [48] 
A172 Brain 1000 µM temozolomide AI 0.5x apoptosis [24] 
A172 Brain 4 nM vincristine AI 0.5x apoptosis [24] 
A375P Melanoma 1 µg/mL 5-FU AI 0.2x apoptosis [49] 
A375P Melanoma 1 µg/mL Cisplatin AI 0.2x apoptosis [49] 
A375P Melanoma 10 ng/mL Paclitaxel AI 0.5x apoptosis [49] 
TXM13 Melanoma 1 µg/mL 5-FU AI 0.3x apoptosis [49] 
TXM13 Melanoma 1 µg/mL Cisplatin AI 0.2x apoptosis [49] 
TXM13 Melanoma 10 ng/mL Paclitaxel AI 0.4x apoptosis [49] 
DM4 Melanoma 1 µg/mL 5-FU AI 0.25x apoptosis [49] 
DM4 Melanoma 1 µg/mL Cisplatin AI 0.3x apoptosis [49] 
DM4 Melanoma 10 ng/mL Paclitaxel AI 0.2x apoptosis [49] 
MDA-MB-231 Breast 15 ng/mL taxol AI 0.3x apoptosis [50] 
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a matrix metalloproteinase that degrades collagen IV, a component of the basement 
membrane, and is strongly associated with invasiveness of tumor cells.  Plasmin, a serine 
proteinase, is also generated in astrocyte/glioma coculture and believed to be involved in 
the activation of MMP2 [47].  A separate study found that the invasiveness of brain cancer 
stem cells, but not other cancer cells, increased 150 - 200% in the presence of astrocytes or 
astrocyte conditioned media [40].   In a monolayer invasion assay, 200% more cancer stem 
cells invaded an astrocyte monolayer as compared to non-stem cells [40].  One of the 
secreted astrocyte proteins found to enhance invasion is IL-6, which has been observed to 
cause a 300% increase in U87 cell invasiveness [36].  This process is thought to involve 
fascin-1, which is upregulated with IL-6 treatment and enhances invasion by increasing 
stiffness of GBM protrusions [36]. 
 In addition to their effect on primary brain cancer cells, astrocytes have been shown to 
have an effect on the invasion and metastasis of brain metastatic cancer cells in vitro.  The 
invasiveness of the melanoma cell lines 70W and B16B15b both increased 150% through 
a heparin sulfate proteoglycan coated transwell chamber in the presence of astrocyte-
conditioned media.  This effect was completely abrogated by the addition of an antibody 
to heparinase, suggesting that factors secreted from astrocytes may increase tumor 
invasiveness by degrading heparin [43].  Enhancement of transendothelial migration 
(representative of metastatic processes) has also been observed with the addition of 
astrocytes to melanoma cell culture [45].  A 200% increase in transendothelial migration 
of YDFR.CB3 melanoma cells was observed in a non-contact co-culture setup.  Treatment 
of astrocytes with an antibody to IL-23 was found to reduce the number of invading cells, 
while the incubation of 10 ng/mL human recombinant IL-23 with tumor cells was found to 
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enhance transendothelial migration by 100% over controls.  Knockdown of MMP2 in 
tumor cells was found to significantly attenuate invasion in both ACM-treated and IL-23 
treated cells, suggesting that MMP2 is involved in the IL-23-mediated invasiveness 
pathway [45].   
 Brain metastatic breast cancer cells have also been shown to exhibit increased invasion 
in the presence of astrocytes.  Brain metastatic breast cancer cells (MDA-MB-231Br), but 
not brain metastatic lung cancer cells (MDA-MB-231) exhibit a 300% increase in 
metastatic growth when cocultured with astrocytes in a soft agar colonization assay [42].  
The invasion of MDA-MB-231Br cells in a Boyden chamber assay increased from zero 
invading cells to hundreds when cultured with astrocyte conditioned media [44].  This 
effect was decreased by approximately 50% when neutralizing antibodies to MMP2 and 
MMP9 were added, again implicating MMPs in the astrocyte-enhanced invasion and 
metastasis of cancer cells [44].  A similar effect of astrocyte conditioned media on H2030 
lung cells has also been observed, with a corresponding decrease in invasion upon the 
addition of MMP neutralizing antibodies [44]. 
 
Chemoprotection 
 The third category in which astrocytes have been shown to facilitate the progression of 
brain cancer is chemoprotection, or protection of tumor cells from chemotherapeutics by 
astrocytes.  This provides yet another barrier to treatment to the already difficult to treat 
gliomas and brain metastatic tumors.  Most chemotherapeutics exhibit low blood-brain 
barrier (BBB) permeability, with the exception of temozolomide [51, 52].  However, it has 
been shown that the BBB becomes compromised at later stages of brain cancer [53], and 
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BBB disruption has also been used in animal models to enhance delivery of other 
chemotherapeutics, such as taxol and vincristine, that have low permeability across the 
intact blood-brain barrier [54].  Both temozolomide and low permeability drugs, however, 
are susceptible to chemoprotection by astrocytes.  In vitro studies have shown that 
astrocytes exhibit protective effects to both primary brain cancer cell lines, and to brain 
metastatic cell lines (Table 2). 
 The human glioblastoma cell line A172 co-cultured with human astrocytes exhibited a 
50 - 60% decrease in cell apoptosis upon treatment with vincristine or temozolomide.   
However, this effect was abolished when the cells were cultured on opposite sides of a 
transwell membrane, indicating that chemoprotection involved paracrine signaling [24]. 
This conclusion was supported by inhibiting gap junctions between astrocytes and glioma 
cells, either through siRNA transfection or treatment with carbenoxolone, which also 
abolished the chemoprotection [24]. 
 Similar effects have been observed in brain metastatic lung [48], breast [48, 50], and 
skin cancer cells [49].  The sequestration of intracellular calcium in astrocytes has been 
implicated in this chemoprotective effect [49].  Support for this hypothesis comes from 
studies that show increases in tumor cell calcium are necessary for chemotherapy-mediated 
apoptosis [55], and that calcium levels increase upon treatment with chemotherapy when 
cancer cells are cultured alone, but not in co-culture with astrocytes [24, 49].  The 
endothelin signaling pathway between astrocytes and brain metastatic breast cancer cells 






 One of the body’s defense mechanisms against cancer is the immune system, which, 
through the action of T lymphocytes and natural killer cells, is able to recognize and injure 
tumor cells [56].  However, several factors secreted by reactive astrocytes have been 
implicated in the protection of cancer cells from the immune system, including tenascin-C 
[56], IL-10 [57], GDF-15 [38], and STAT3 [56].  While no studies have directly implicated 
astrocytes in the immune protection of glioma cells, all of the aforementioned factors have 
been shown to be upregulated in reactive astrocytes [12], and are known to be involved in 
immune protection.  Tenascin-C, an extracellular matrix glycoprotein, has been shown to 
inhibit T-cell transmigration through tumor monolayers [58].  Glioma cell lines, which 
secrete tenascin-C, allow for greatly decreased transmigration of glioma cells as compared 
to MCF-7 breast cancer cells.  However, the addition of 10 µg/mL of tenascin-C to MCF-
7 cells resulted in 50% decrease in T-cell transmigration [58].  It has also been shown that 
inhibition of STAT3 in mouse tumors allows for enhanced activation of tumor 
macrophages [59].  STAT3 is also involved in suppressing proinflammatory cytokine 
release, which inhibits the response of T-cells to tumors [56].  IL-10 has been implicated 
in suppressing the immune response to glioma through inhibiting monocyte activation by 
down-regulating monocyte MHC class II expression [60], as well as inhibiting IL-2 
induced T-cell proliferation [57].   GDF-15, a member of the TGF-β family highly 
expressed in glioma cells and reactive astrocytes, has been shown to inhibit immune-
mediated tumor cell lysis. A 100% increase in NK specific lysis was observed in SMA-
560 glioma cells upon knockdown of GDF-15 [38].  This process likely involves IL-10 as 
well, as decreased levels of IL-10 were noted in the GDF-15 knockdown culture [38]. 
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 Many of these factors implicated in cancer immune suppression are expressed both by 
astrocytes and by glioma cells themselves, which complicates evaluation of the relative 
effect of astrocyte activation.  It is worth noting, however, that several of these factors, 
such as tenascin-C [58] and IL-10 [61], are not expressed in other cancer types such as 
melanoma and breast cancer, and therefore the secretion of these factors by astrocytes may 
play an enhanced role in brain-metastatic cancers. 
 
In Vivo Activation Studies 
 While assessment of the effects of astrocyte activation on tumor progression is 
extremely difficult in vivo, several methods of visualizing and quantifying astrocyte 
reactivity in response to brain tumors have been established [15].  GFAP, an intermediate 
filament protein strongly upregulated in reactive gliosis [12], is often used as a marker for 
visualization of astrocyte activation, both in vivo and in vitro [42]. GFAP-luciferase mice 
have been used both to image and quantify the degree of astrocyte activation in the vicinity 
of fluorescently labeled glioma or breast cancer tumors [16].  For both tumor types, a 
transient increase in GFAP expression occurred in the week following cancer cell injection, 
followed by a steady increase in GFAP activity over the next several weeks.  Astrocyte 
activation increased directly with tumor burden, indicating a relationship between tumor 
size and the degree of reactive gliosis [16].  The size of the reactive astrocyte region around 
a tumor can range from a single layer of astrocytes from small tumors [42] to the entire 
ipsilateral brain hemisphere for very large tumors [16]. 
 Several other imaging techniques have been used to visualize reactive gliosis in live 
animals, although not in conjunction with a tumor model.  Both MRI and SPECT imaging 
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have been used to image astrocyte activation, taking advantage of the metabolic changes 
associated with reactive gliosis and utilizing astrocyte specific radiolabels, respectively 
[15]. 
 While the in vivo data involving astrocyte activation and cancer progression is limited, 
it supports the mass of in vitro data on the influence of astrocytes on cancer progression. 
Future in vivo and ex vivo experiments should be designed to determine the effects of 
reactive gliosis on brain cancer, though the relative effects of astrocytes on cancer 
progression in vivo may be difficult to determine, as many factors secreted by reactive 




Chapter 2: Influence of basement membrane proteins and endothelial 
cell-derived factors on the morphology of human fetal-derived astrocytes 
in 2D 
Abstract 
Astrocytes are the most prevalent type of glial cell in the brain, participating in a variety of 
diverse functions from regulating cerebral blood flow to controlling synapse formation.  
Astrocytes and astrocyte-conditioned media are widely used in models of the blood-brain 
barrier (BBB), however, very little is known about astrocyte culture in 2D.  To test the 
hypothesis that surface coating and soluble factors influence astrocyte morphology in 2D, 
we quantitatively analyzed the morphology of human fetal derived astrocytes on glass, 
Matrigel, fibronectin, collagen IV, and collagen I, and after the addition soluble factors 
including platelet-derived growth factor (PDGF), laminin, basic fibroblast growth factor 
(bFGF), and leukemia inhibitory factor (LIF).  Matrigel surface coatings, as well as 
addition of leukemia inhibitory factor (LIF) to the media, were found to have the strongest 
effects on 2D astrocyte morphology, and may be important in improving existing BBB 
models.  In addition, the novel set of quantitative parameters proposed in this paper provide 
a test for determining the influence of compounds on astrocyte morphology, both to screen 
for new endothelial cell-secreted factors that influence astrocytes, and to determine in a 





 The human brain is composed primarily of neurons and glia along with the cells 
associated with the brain vasculature.  Astrocytes are the most prevalent of the glial cells, 
participating in a variety of diverse functions from regulating cerebral blood flow to 
controlling synapse formation [2, 4, 7, 25, 62, 63].   The complex star-shaped morphology 
of astrocytes, with their many branched and tortuous protrusions, allows for the cells to 
contact multiple neurons and capillaries, regulating blood flow, enhancing blood-brain 
barrier tightness, and maintaining water and ion homeostasis [4, 7, 25, 62, 63]. 
 In the human brain there are four classes of astrocytes:  interlaminar, protoplasmic, 
fibrous, and varicose projection astrocytes.  All express glial fibrillary acidic protein 
(GFAP) and are found in different layers of the cerebral cortex [26]. Protoplasmic 
astrocytes, the most common type in the brain, have specialized end-feet that interact with 
capillaries and neurons in the brain’s gray matter.  Human astrocytes are generally larger 
and more complex that in rodents.  For example, protoplasmic astrocytes in humans are 
about 150 µm in diameter and have about 40 main processes emanating from the cell body 
[7].   In contrast, mouse protoplasmic astrocytes have an average diameter of about 60 µm 
and about 5 main processes [7].   
 Astrocytes in the human brain interact with endothelial cells through end-feet that 
almost completely cover the entire capillary surface [7].  The basement membrane 
surrounding the endothelial cells and separating the capillaries from the astrocytes is 
comprised of laminin and collagen type IV along with other proteins such as fibronectin 
and perlecan [64-66].  Astrocytes participate in blood-brain barrier function by increasing 
18 
 
tight junction formation, the expression and polarization of transporters, and specialized 
enzyme systems [4, 7, 67, 68].   
 Although many of the details of astrocyte regulation of the blood-brain barrier remain 
to be elucidated, astrocytes and astrocyte-conditioned media are widely used in 2D cell 
culture models of the blood-brain barrier [6, 69].  In vitro permeability measurements 
typically involve seeding a confluent monolayer of brain capillary endothelial cells on top 
of a permeable transwell support with astrocytes, and sometimes pericytes, cultured in 2D 
on the opposite side of the membrane [23, 70-72].  The morphology of these astrocytes, 
however, is rarely shown or discussed.  Since astrocytes rarely display an astrocytic 
phenotype in 2D culture, this is a potential issue contributing to the lack of BBB 
characteristics (high electrical resistance and low permeability) of most transwell-based 
BBB models. 
 Blood-brain barrier models generally use rodent-derived astrocytes.  However, in 2D 
cell culture, the fraction of cells exhibiting an astrocyte-like morphology with processes 
extending from a rounded cell body is very low, although endothelial derived factors are 
known to play a role in inducing an astrocytic morphology [20, 73-75].   The morphology 
of protoplasmic astrocytes in the human brain is significantly different that in the mouse 
brain [7], however, very little is known about human astrocytes and their morphology in 
cell culture. 
 Here we report on the morphology of human fetal-derived astrocytes in 2D cell culture.  
To quantitatively determine the influence of basement membrane proteins and soluble 
factors on astrocyte morphology in 2D cell culture, we analyzed the morphology of cells 
on various physiologically relevant coatings, including Matrigel, fibronectin, collagen IV, 
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and collagen I, and after the addition soluble factors including platelet-derived growth 
factor (PDGF), laminin, basic fibroblast growth factor (bFGF), and leukemia inhibitory 
factor (LIF).  We show that Matrigel coating significantly increases the fraction of 
astrocytic cells and increases the degree of branching, and the number of branch points.  
Laminin, bFGF, and LIF result in a significant increase in the fraction of cells with 
astrocytic morphology.  Co-culture of astrocytes on a confluent monolayer of brain 
microvascular endothelial cells results in a very large fraction of astrocytic cells with more 
protrusions and higher tortuosity. 
 
Materials and Methods 
Astrocyte and Endothelial Cell Culture 
 Following approval by the Johns Hopkins University Institutional Review Board, 
primary cultures of human fetal-derived astrocytes were obtained as described previously 
[76, 77].  Briefly, intraoperative human central nervous system (CNS) tissues, gestational 
weeks 19 - 21, which were obtained following written informed consent for clinical 
procedures, were used for this research since they were considered to be pathological 
waste.   Tissue was mechanically dissociated and cells number and viability was 
determined by trypan blue incorporation.  Neural cells were first cultured as neurospheres 
in suspension in low adherent flasks using DMEM/F12 (sigma) medium with 2% B27 
supplement, 1% penicillin-streptomycin (Invitrogen), 20ng mL-1 of EGF (peprotech) and 
bFGF (peprotech), 10 ng mL-1 of LIF (millipore), and 5 g mL-1 of heparin (sigma). To 
induce the formation of astrocytes, neurospheres were mechanically dissociated and single 
cells were plated on tissue culture flasks in DMEM/f12 medium (Sigma) supplemented 
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with 10% fetal bovine serum (Sigma) and 1% penicillin-streptomycin (Invitrogen).  Human 
brain microvascular endothelial cells (HBMECs) were isolated from an adult brain and 
immortalized by transfection with SV40 [78]. While immortalized human brain endothelial 
cells typically do not form tight junctions with low permeability and high transendothelial 
resistance, they have the advantages of being widely available and commonly used cells in 
BBB models.  A recent study showed that the HBMEC cell line used in these experiments 
has the highest TEER values, and expresses ZO-1, VE-cadherin, and claudin-5 [79].  In 
addition, these cells express basement membrane proteins relevant for this study, including 
fibronectin, laminin, and collagen IV. 
 
Extracellular Matrix Protein Coatings 
 Nunc Lab Tek II 2-well chamber slides (0.7 cm2) were coated in the following 
extracellular matrix (ECM) components: fibronectin, collagen IV, Matrigel (phenol red-
free, growth factor reduced), and collagen I.  Fibronectin, collagen IV, and Matrigel (BD 
Biosciences) were diluted to concentrations of 100 μg mL-1 in phosphate buffered saline 
(PBS, Invitrogen).  Wells were coated with 100 μL cm-2 diluted ECM proteins for 2 hours 
at 4 ˚C.  Wells were washed once with PBS before cell seeding.  Rat tail collagen I (BD) 
was diluted to a concentration of 100 μg mL-1 in 0.02 M acetic acid.  Wells were coated 
for 1 hour at 37 ̊ C and washed three times with PBS.  Uncoated glass was used as a control.  
Astrocytes were seeded on the coated dishes at a concentration of 5,000 cells cm-2.  For the 
co-culture experiments, HBMECs were seeded onto 2-well chamber slides at a 
concentration of 50,000 cells cm-2.  Cells were grown to confluence for 48 hours in M199 
media.  After confluence was reached, the medium was replaced with DMEM/f12 and 
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astrocytes were seeded on top of the monolayer at a density of 5,000 cells cm-2.  In all 
experiments, astrocytes were fixed after 24 hours.  All experiments on coated surfaces were 
performed in triplicate. 
 
Soluble Factors 
 Astrocytes were seeded at a concentration of 5000 cells cm-2 onto 2-well chamber 
slides.  Cell culture media was supplemented with 10 ng mL-1 platelet-derived growth 
factor (PDGF) (Sigma P4056), laminin (Sigma, L2020), basic fibroblast growth factor 
(bFGF) (Millipore, GF003), or leukemia inhibitory factor (LIF) (Sigma, L5283).  
Unsupplemented astrocyte media was used as a control. 
 
Immunofluorescence Microscopy and Image Analysis 
 Cells were fixed in 3.7% formaldehyde after 24 hours of culture.  After fixing for 10 
minutes at room temperature, cells were washed with PBS three times and permeabilized 
with 0.01% Triton-X 100 (Sigma) for 5 minutes.  Cells were then washed with PBS and 
blocked with 10% donkey serum (Millipore) in PBS for 30 minutes at room temperature.   
Cells were then incubated with primary antibodies in 10% donkey serum overnight at 4 ˚C.  
Goat anti-glial fibrillary acidic protein (aGFAP, Santa Cruz) was used at a dilution of 1:50 
to label astrocytes. Rabbit anti-zona occludens-1 (ZO-1, BD) was used at a dilution of 
1:200 to label endothelial cell tight junctions.  Cells were washed with PBS three times for 
five minutes each following primary antibody incubation, and then incubated with 
secondary antibodies in 10% donkey serum for 1 hour at room temperature.  Donkey anti-
goat IgG 488 and donkey anti-rabbit IgG 568 (Invitrogen) were used to fluorescently label 
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the GFAP and ZO-1, respectively, and DAPI was used to stain nuclei.  Cells were washed 
with PBS three times before imaging.   
 Fluorescence images were acquired with a Nikon TiE microscope equipped with a 
Photometrics camera using NIS elements software.  Experiments were designed such that 
the density of adherent cells was sufficiently low for single cell imaging.  Images were 
recorded of adherent cells at random locations in the wells.  For analysis of the number of 
astrocytic and non-astrocytic cells, all recorded images, including those with multiple cells, 
were included.  For detailed morphological analysis of astrocytic cells expressing 
protrusions, only images of isolated cells were analyzed.   Cells expressing astrocyte-like 
processes were traced in ImageJ and analyzed for the following morphological parameters: 
number of primary, secondary, and tertiary protrusions emanating from the main cell body, 
cell body area, total protrusion length, the overall size (defined by the diameter of the 
smallest circle that can enclose the cell and all of its processes), the number of branch 
points (the sum of secondary and other higher order branches), and the degree of branching 
(number of branch points divided by the number of primary protrusions).   
 
Results and Discussion 
Influence of basement membrane proteins on astrocyte morphology 
 To assess the role of basement membrane proteins on the morphology of human fetal-
derived astrocytes, cells were seeded on various physiologically relevant coatings (Figure 
3).  Only 23% of astrocytes seeded on glass exhibited astrocyte-like morphology.  Rat tail 
collagen I, which is largely absent in the smaller vessels of the brain, resulted in 29% of 
cells with processes, a small increase in compared to the control.  Collagen IV (44%) and 
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fibronectin (51%), both present in the basement membrane at the BBB, resulted in a further 
increase in the number of astrocytic cells compared to the controls.  However, when seeded 
on Matrigel prepared from purified mouse basement membrane, the fraction of astrocytic 
cells increased to 64%.  For comparison astrocytes were also seeded on confluent 
monolayers of HBMECs (Figure 3G), resulting in 92% of the cells with astrocyte-like 
protrusions. These results indicate that basement membrane proteins and endothelial cells 
have a strong influence on the formation of astrocytic processes in 2D cell culture.   
 
Figure 3:  Influence of ECM coating on astrocyte morphology after 24 hours.  Fluorescence images of astrocytes 
stained for GFAP (green) and DAPI (blue) on (A) glass, (B) collagen I, (C) collagen IV, (D) fibronectin, (E) Matrigel, 
and (F) co-culture on a confluent monolayer of HBMECs.  (G)  Astrocyte (from panel (F)) seeded on a confluent 
monolayer of HBMECs, stained for GFAP (green), DAPI (blue), and ZO-1 (red).  (H) The percentage of cells with 
protrusions.  Total number of cells analyzed: uncoated (N = 103), collagen I (N = 85), collagen IV (N = 61), fibronectin 
(N = 63), Matrigel (N = 54), co-culture (N = 58). 
 All of the cells expressing astrocyte-like processes were analyzed for the following 
morphological parameters: number of primary, secondary, and tertiary protrusions 
emanating from the main cell body, cell body area, total protrusion length, the overall size, 
the number of branch points, and the degree of branching. Although the number of branch 
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points and the degree of branching are parameters derived from the number of primary, 
secondary, and tertiary protrusions, they provide complementary information and are 
useful in comparison to the literature.  In addition, the protrusion tortuosity () was 
determined from   = /c where  is the arc length of the processes and c is the shortest end-
to-end distance.    
 First we summarize the results for astrocyte morphology on coated surfaces compared 
to the uncoated glass control (Figure 4).   In general, astrocytic cells on coated surfaces 
exhibited 5 - 10 primary protrusions and an overall diameter of 200 - 300 µm.   For 
astrocytes on collagen I and collagen IV, the overall cell diameter, the number of primary, 
secondary, and tertiary protrusions, as well as the total protrusion length were not 
statistically different from the uncoated controls.  The morphology of astrocytes on 
fibronectin was also similar to the uncoated controls for most parameters.  In contrast, for 
astrocytes seeded on Matrigel, the number of primary (10.4 ± 0.9) and secondary (4.7 ± 
1.1) protrusions, the overall protrusion length (921 ± 130 µm), the number of branch points 
(5.1 ± 1.3), and the degree of branching (1.5 ± 0.1) were significantly higher than the 
control (6.0 ± 0.8 primary and 1.0 ± 0.3 secondary protrusions, 365 ± 79 µm total protrusion 
length, 1.0 ± 0.3 branch points, and a degree of branching of 1.1 ± 0.1).  These results 
suggest that Matrigel plays a significant role in eliciting astrocyte morphology in 2D.    
 The overall diameter of astrocytic cells on basement membrane proteins or a confluent 
monolayer of endothelial cells (200 - 300 µm) is larger than for astrocytes in the human 
brain (about 150 µm), whereas the number of primary protrusions (5 - 10) is lower (about 
40) [7].  These results are not surprising since the human fetal derived astrocytes are 
confined to two-dimensional growth.  However, the size and number of processes are 
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significantly larger than for astrocytes in the mouse brain where the average size is about 
60 µm and there are about 5 main processes [7].   
 Co-culture of human fetal-derived astrocytes on confluent monolayers of brain 
microvascular endothelial cells was found to dramatically enhance astrocyte morphology 
over controls (Figure 3 and Figure 4).  Astrocytes cultured on endothelial cells exhibited a 
similar number of primary protrusions (6.8 ± 0.8), compared to the uncoated controls (6.0 
± 0.4), but a significant increase in the number of secondary (8.9 ± 0.66) and tertiary (2.9 
± 0.38) protrusions compared to the control (1.0 ± 0.31 secondary and 0 tertiary 
protrusions), resulting in a large number of branch points (11.8 ± 1.0) and a high degree of 
branching (3.0 ± 0.2) compared to the control (1.0 ± 0.3 branch points and a degree of 
branching of 1.1 ± 0.1).  The cell body area (661 ± 55 µm2) and the overall diameter (301 
± 27 µm) were smaller than the uncoated control (1200 ± 171 µm2 and 193 ± 14 µm, 
respectively).  The small cell body area may be related to the localization of expression of 
ECM proteins to the cell-cell junctions in the HBMEC monolayer.  In addition, the 
processes often followed cell-cell boundaries, implicating ECM proteins and possibly 
soluble factors secreted by the endothelial cells in influencing astrocyte morphology.  Brain 
capillary endothelial cells are known to produce fibronectin, laminin, and collagen IV in  
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culture [64].    
Figure 4:  Influence of surface coatings on astrocyte morphology.  (A) The cell area defined by the area of the cell body. 
(B) the cell diameter is overall size defined by the diameter of the smallest circle that can enclose the cell and all of its 
processes.  (C) The protrusion length is the total length of all protrusions.  (D) The degree of branching is the number of 
branch points divided by the number of primary protrusions. (E) The number of primary protrusions represents the 
number of protrusions emanating from the cell body. (F) The number of secondary protrusions represents protrusions 
emanating from primary protrusions. (G) The number of tertiary protrusions represents protrusions emanating from 
secondary protrusions. (H) The number of branch points represents the sum of secondary and other higher order 
protrusions (equivalent to the number of bifurcations).  Data represent mean ± SE.  Statistical significance was determined 
using a student’s t-test test.  *** P ≤ 0.01, ** P ≤ 0.05, * P ≤ 0.1.  Only cells with astrocyte-like morphology were 
analyzed (the total number of cells and the fraction of cells with astrocyte-like morphology are provided in Figure 3). 
 The important role of ECM proteins was further confirmed by seeding astrocytes on 
patterned surfaces.  Astrocytes seeded on HBMEC-derived ECM after lysis of a confluent 
monolayer of HBMECs (Figure 5A) showed cells with smaller cell bodies, and branched, 
tortuous processes, similar to the morphology of astrocytes seeded on HBMEC monolayers 
(Figure 3G).   Astrocytes on micropatterned fibronectin rings (Figure 5B) showed similar 
features, where many processes were seen to follow the ring patterns, and the astrocyte cell 
bodies tended to be much smaller than on the uniformly fibronectin-coated glass. 
 In contrast to cells seeded on glass coated with basement membrane proteins, cells 
seeded on a confluent monolayer of endothelial cells showed a significant increase in all 
parameters except cell body area and the number of primary protrusions (Figure 4).  The cell 
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body area decreased from 1200 to 661 µm2 on the endothelial cell monolayer.  While the 
number of primary protrusions was similar to cells on uncoated glass, the number of branch 
points and degree of branching was significantly increased and larger than on the coated 
glass.  
 Collagen I and IV, fibronectin and Matrigel all promote an increase in cell body area 
(Figure 4A) compared to uncoated glass.  In contrast, the cell body area was significantly 
smaller for astrocytes on a monolayer of endothelial cells (Figure 3G), on HBEMC-derived 
ECM (Figure 5A), or on fibronectin rings (Figure 5B).  The end-feet of astrocytes in the 
brain are in contact with basement membrane proteins whereas the cell body is in contact 
with interstitial fluid and the hyaluronic acid-based extracellular matrix.  Our results 
suggest that the lack of contact with basement membrane proteins plays a role in 
minimizing the cell body area in the brain.  Therefore, in cell culture, surfaces patterned 
with basement membrane proteins or endothelial cell monolayers result in morphologies 
that more closely resemble astrocytes in the brain.  
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 Primary murine astrocytes seeded on poly-lysine modified surfaces have been shown 
to express processes in less than 5% of cells [20].  Three days after the addition of a Rho 
GTPase inhibitor (the Clostridium botulinum C3 toxin), over 80% of these primary murine 
astrocytes expressed protrusions.  Analysis of the astrocytic cells revealed that the total 
protrusion length increased from about 300 µm to about 800 µm and the number of branch 
points increased from about 1 to about 8 [20].  The total protrusion length of human fetal-
derived astrocytes on Matrigel (920 µm) or co-culture (1200 µm), and the number of 
branch points (5.1 on Matrigel and 11.8 on co-culture) are similar (Figure 4), suggesting that 
the Rho GTPase inhibitor may modulate the same pathways as the factors secreted by the 
HBMECs.  
 The straightness of the protrusions was assessed by measuring the tortuosity,  (  = 
/c) For a straight line   = 1, whereas for a circle   = ∞.   The tortuosity of the processes 
was slightly higher on fibronectin, collagen I, and Matrigel compared to the uncoated 
surface.  However, the tortuosity was significantly higher in co-culture where the processes 
tended to follow the cell-cell boundaries.  
Figure 5:  Tortuosity of astrocytes. (A) Immunofluorescence image of an astrocyte on HBMEC-
derived ECM.  Endothelial cells were grown to confluence on glass-bottom dishes, and removed from 
the dish with a lysis buffer containing 0.5% Triton X-100 and 20 mM NH4OH in PBS.  (B) 
Immunofluorescence image of an astrocyte on 50 μm inner diameter fibronectin rings.  Astrocytes 
tended to trace the rings and have smaller cell bodies like those seen in co-culture.  Fibronectin (red), 
GFAP (green).  (C) Tortuosity of astrocytes on surface coatings and in co-culture.  The tortuosity () 
is given by   = /c where  is the arc length of the processes and c is the shortest end-to-end distance. 
For a straight line   = 1, whereas for a circle   = ∞.   While all of the surface coatings result in very 
small increases over the control, the astrocytes in co-culture have significantly higher tortuosities.  




Influence of endothelial cell-expressed soluble factors on astrocyte morphology 
 To elucidate the role of soluble factors expressed by endothelial cells, human fetal-
derived astrocytes seeded on uncoated glass were incubated with platelet-derived growth 
factor (PDGF), laminin, basic fibroblast growth factor (bFGF), or leukemia inhibitory 
factor (LIF), for 24 hours to determine their influence on astrocyte morphology.  PDGF is 
expressed in brain capillaries and, in addition to recruiting pericytes to the BBB [80], 
promotes division and inhibits differentiation of glial cells from the rat optical nerve [81].  
Laminin is an extracellular matrix protein present in the basement membrane and is known 
to promote neurite outgrowth in vitro [82].  bFGF is expressed by both astrocytes and 
endothelial cells at the BBB.  LIF is expressed by endothelial cells and has been shown to 
induce astrocyte differentiation [75].  While the mechanism of LIF-induced astrocyte 
differentiation is not well characterized, it is thought to involve glycoprotein 130 dependent 
signaling pathways [83]. 
 All of the soluble factors studied here increased the fraction of astrocytes with 
processes (Figure 6A).   The addition of PDGF (28%), laminin (54%), bFGF (62%), or LIF 
(70%) resulted increases in the fraction of cells with astrocyte-like morphology compared 
to the controls (23%). Indeed, the addition of LIF to cells seeded on uncoated glass resulted 





Figure 7:  Influence of soluble factors on astrocyte morphology.  Data represent mean ± SE.  Statistical significance was 
determined using a student’s t-test.  *** P ≤ 0.01, ** P ≤ 0.05, * P ≤ 0.1.  See Figure 4 for the number of cells analyzed.  
 The addition of these soluble factors did not result in any systematic differences in cell 
morphology.  However, LIF had a statistically significant effect on the cell body area (767 
± 59 µm2), which was smaller than the control media (1440 ± 316 µm2), and similar to the 
cell body area observed in co-culture (660 ± 55 µm2) (Figure 4A).    
Figure 6:  Morphological analysis of astrocytes cultured on glass with the additional of soluble factors.  (A) 
Percentage of cells with protrusions.  Control (N = 79), PDGF (N = 81), laminin (N = 68), bFGF (N=71), LIF 
(N = 74).  Immunofluorescence images of (B) control and (C) astrocytes treated with LIF stained for GFAP 
(green) and DAPI (blue). 
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 Both co-culture with vascular endothelial cells and the addition of LIF have been shown 
to increase the fraction of GFAP positive rat astrocyte precursor cells, suggesting that LIF 
plays an important role in astrocyte induction [75].  These studies suggest that vascular 
endothelial cells are the source of LIF for astrocyte differentiation, however, the correlation 
between GFAP expression and cell morphology was not reported [75].  In a related study, 
the culture of primary mouse astrocytes in brain capillary endothelial cell conditioned 
media was found to qualitatively increase the number of cells with processes [74].  
 These results have implications for the design of 2D transwell models for the blood-
brain barrier and more broadly on the role of brain microvascular endothelial cells in 
regulating astrocyte morphology and function.  While the use of astrocytes in 2D models 
of the blood-brain barrier is very common and known to increase transendothelial electrical 
resistance, their morphology is usually ignored, and may be an overlooked factor 
contributing to the lack of reproducible protocols.   Furthermore, human fetal-derived 
astrocytes provide a potential source of cells for blood-brain barrier models using human 
cells.  In addition, the approach developed here could be used to assess the role of other 
cell-derived factors on astrocyte morphology, further advancing the understanding of 
astrocyte interactions at the blood-brain barrier and determining which factors are most 







Table 3: Tabulated summary of key findings.  Details of the differences between the various analyzed conditions and the 
uncoated glass controls, and percentage of cells displaying astrocytic morphology. 
Condition Cell Morphology % 
Astrocytic 
Coatings   
Uncoated glass 
control 
Small cell bodies, relatively short, straight and 
unbranched processes 
64% 
Collagen I coating Larger cell bodies than controls, with slightly more 
tortuous processes 
23% 
Collagen IV coating Larger cell bodies than controls 29% 
Fibronectin coating Increased protrusion number, length, and tortuosity 
compared to controls 
44% 
Matrigel coating Larger cell body area than controls, with significant 
increases in protrusion number, branching, length, 
tortuosity, and diameter 
51% 
HBMEC coculture Small cell bodies, long, branched, tortuous processes 92% 
Soluble factors   
PDGF in media No difference from uncoated glass controls 28% 
Laminin in media No difference from uncoated glass controls 54% 
bFGF in media No difference from uncoated glass controls 62% 





Figure 8: Low magnification images of astrocytes on different surface coatings.  In all cases about 25,000 cells cm-2 
were seeded into 0.7 cm2 wells for 24 hours.  These images show the large diversity of astrocyte phenotypes, from 
fibroblast-like cells to more physiological cells expressing protrusions.  While the amount of adherent cells varies very 
little between the different surface conditions, the amount of cells expressing protrusions is significantly greater on the 




 In this study, it was determined which soluble factors and basement membrane proteins 
typically secreted by endothelial cells in the BBB play a role in obtaining more 
physiological human fetal-derived astrocyte morphology in 2D in vitro platforms.   2D 
astrocytes will never be a fully physiological platform due to the fact that astrocytes in vivo 
have inherently 3D morphologies, and nearly 95% of the cells assayed expressed high 
degrees of GFAP, indicative of reactive astrocytes.  However, many common in vitro 
assays, especially those involving BBB transport and permeability, typically involve 
astrocytes cultured in 2D, without necessarily reporting on astrocyte morphology in these 
models.  In these experiments, we determined that coculture on human brain microvascular 
endothelial cells resulted in the most astrocytes expressing physiological processes, and 
that coatings with Matrigel and the addition of LIF and bFGF to cell culture media are also 
able to increase the amount of astrocytes expressing increased physiological morphologies 




Chapter 3: Human astrocytes develop physiological morphology and 
remain quiescent in a novel 3D matrix. 
Abstract 
Astrocytes are the most abundant glial cells in the brain and are responsible for diverse 
functions, from modulating synapse function to regulating the blood-brain barrier. In vivo, 
these cells exhibit a star-shaped morphology with multiple radial processes that contact 
synapses and completely surround brain capillaries. In response to trauma or CNS disease, 
astrocytes become activated, a state associated with profound changes in gene expression, 
including upregulation of intermediate filament proteins, such as glial fibrillary acidic 
protein (GFAP). The inability to recapitulate the complex structure of astrocytes and 
maintain their quiescent state in vitro is a major roadblock to further developments in tissue 
engineering and regenerative medicine. Here, we characterize astrocyte morphology and 
activation in various hydrogels to assess the feasibility of developing a matrix that mimics 
key aspects of the native microenvironment. We show that astrocytes seeded in optimized 
matrix composed of collagen, hyaluronic acid, and Matrigel exhibit a star-shaped 
morphology with radial processes and do not upregulate GFAP expression, hallmarks of 
quiescent astrocytes in the brain. In these optimized gels, collagen I provides structural 
support, HA mimics the brain extracellular matrix, and Matrigel provides endothelial cell 
compatibility and was found to minimize GFAP upregulation. This defined 3D 
microenvironment for maintaining human astrocytes in vitro provides new opportunities 





 Astrocytes, the most prevalent type of glial cell in the brain, have traditionally been 
considered supporting cells for neural function.  However, it is now recognized that 
astrocytes participate in a range of brain functions, including regulating the formation and 
dissolution of synapses, maintaining and repairing the blood-brain barrier, and responding 
to tissue damage [2, 4, 26, 63].  In response to trauma or pathological tissue damage 
astrocytes become activated, a process known as reactive gliosis [13, 84, 85].  While 
activated astrocytes help to repair damage in the brain, they have also been implicated in 
causing neural damage [26, 84], and accelerating tumor growth and invasiveness [42, 47].  
Astrocyte activation is characterized by marked changes in protein expression [13, 85, 86], 
a hallmark of which is the increased expression of glial fibrillary acidic protein (GFAP) 
[13, 19].    
 Astrocytes typically have star-shaped morphologies with small cell bodies, and radial 
branched processes, and occupy distinct domains [7].  Protoplasmic astrocytes in the 
human cortex, have a cell body approximately 10 µm in diameter and an overall diameter 
of about 150 µm [7].  Astrocyte processes have been estimated to contact tens of thousands 
of neural synapses per cell [87], while process end-feet also completely surround brain 
capillaries [7].  GFAP is widely used as a marker for astrocyte identification [25]. 
 The brain microenvironment plays a crucial role in regulating astrocyte structure and 
function.  The brain is composed mostly of neurons and glial cells, which account for 75 - 
90% of the total brain volume [88, 89] (Figure 9).  The extracellular space contains a 
complex extracellular matrix that is primarily composed of hyaluronic acid (HA), 
proteoglycans, and tenascins [90, 91].  In addition, laminin is present in small quantities in 
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the developing brain and in the injured adult brain [92].  Many common extracellular 
matrix proteins, such as fibronectin and collagen, are not present in the brain [90].   
 
Figure 9: Illustration of lack of extracellular space in the brain. 
 There are two major challenges in culturing astrocytes for brain research: (1) achieving 
physiological cell morphology and (2) maintaining a quiescent or non-activated state with 
low levels of GFAP expression. Rat astrocytes in primary cultures containing 
collagen adopt a rounded morphology with short processes and express high levels of 
GFAP expression after 24 h in culture [18].  Similar rounded morphology and high levels 
of GFAP expression were reported for a human astrocyte cell line in gels with 1 mg mL-1 
collagen and different concentrations of HA [22].  Mouse astrocytes cultured in scaffolds 
formed from 1.2 µm diameter electrospun polyurethane fibers coated with poly-L-ornithine 
or lysine showed long, branched processes but exhibited high levels of GFAP expression 
[19], demonstrating that the local microenvironment has a profound influence on astrocyte 
phenotype.  These studies highlight the difficulty in recapitulating the characteristic 
morphology and non-activated state in cell culture.  Here we recapitulate the morphology 
and very low levels of activation of quiescent human astrocytes. 
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 We hypothesized that astrocytes cultured in a 3D matrix that provides structural support 
and appropriate extracellular matrix factors will recapitulate the characteristic star-shaped 
morphology and low levels of GFAP expression typical of quiescent astrocytes.  To test 
this hypothesis, we cultured human fetal derived astrocytes in four classes of gels:  HA 
gels, collagen gels, collagen/HA gels, and gels composed of collagen, HA, and Matrigel.  
We show that astrocytes cultured in gels with collagen I for structural support (provided in 
vivo by the high density of cell processes and dendrites), HA to mimic the brain ECM, and 
Matrigel for endothelial cell compatibility, exhibit a highly branched morphology and very 
low levels of activation.  Recapitulating the physiological properties of astrocytes in this 
in vitro environment provides a new platform to explore the role of astrocytes in diverse 
functions, such as cell and tissue regeneration, blood-brain barrier regulation, and effect on 
brain tumor progression. 
 
Materials and Methods 
Cell culture 
 Primary human fetal-derived astrocytes were obtained as described previously [76, 93, 
94], following approval by the Johns Hopkins University Institutional Review Board.  
Intraoperative human central nervous system tissues, gestational weeks 19 - 21, which were 
following written informed consent for clinical procedures, were used for this research as 
they are considered pathological waste.   Neural cells were cultured first in suspension as 
neurospheres in low adherent flasks using DMEM/F12 (Sigma) medium with 2% B27 
supplement, 1% penicillin-streptomycin (Invitrogen), 20ng mL-1 of EGF (Peprotech) and 
bFGF (Peprotech), 10 ng mL-1 of LIF (Millipore), and 5 g mL-1 of heparin (Sigma). In 
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order to obtain astrocytes, neurospheres were mechanically dissociated and single cells 
were plated on tissue culture flasks in DMEM/f12 medium (Sigma) supplemented with 
10% fetal bovine serum (Sigma) and 1% penicillin-streptomycin (Invitrogen). To ensure 
that the cell population did not contain microglia, cells were stained for CD11b (AbCam).  
The lack of CD11b positive cells confirmed that there was no contamination by microglia.  
 
3D astrocyte culture in hydrogels 
 Cells were seeded in various combinations of ECM protein hydrogels (Table 4) at a 
concentration of approximately 10,000 cells mL-1.  Collagen gels were formed by 
neutralizing rat tail collagen I (BD) with NaOH, according to the manufacturer’s 
instructions.  10X DMEM/F12 (Sigma) and astrocytes in cold, serum-free media were then 
added to the neutralized collagen.  For the mixed gels, hyaluronic acid (HA, Glycosan 
HyStem Kit) was combined with poly(ethylene glycol) diacrylate (PEGDA) cross-linker 
(Glycosan Xtralink) at the manufacturer’s recommended ratio (8:1 ratio of HA: 
crosslinker).  The cross-linked HA was then added to the neutralized collagen, followed by 
the growth factor reduced Matrigel (BD), if applicable, followed by the 10X media and 
cells.  All gels were formed in an ice water bath under sterile conditions, and gels were 
seeded into Nunc Lab Tek II 8-well chamber slides.  Wells and pipet tips were kept in the 
freezer prior to mixing the gels, to ensure thorough mixing before gelation occurred.   
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Table 4: Summary of hydrogel compositions studied. Concentrations are in mg mL-1. 
 
Physical characterization of the gels 
 The structure of the gels was characterized using scanning electron microscopy.  
Acellular gels were prepared as described above, with additional serum-free media to 
replace the volume of cells.  Gels were incubated with deionized water overnight and then 
frozen with liquid nitrogen.  The gels were then lyophilized overnight, mounted on stubs, 
and coated with platinum.  Gels were imaged using a scanning electron microscope (FEI 
Quanta 200 Environmental SEM) under vacuum at 2.5 kV. 
 The mechanical properties of the gels were characterized using an atomic force 
microscope [95].  A Dimension 3100 AFM (Bruker Nano, Santa Barbara, CA) was used 
for the AFM measurements.  The measured spring constant and length of the cantilever 
was 4.22 N m-1 and 225 μm, respectively (Budget Sensors; MagneticMulti75-G 
Cantilever).  A 50 μm diameter soda lime glass microsphere (Polysciences, Inc., 
Warrington, PA) was attached to the end the cantilever using fast setting epoxy (Hardman, 
Royal Adhesives and Sealants, South Bend, IN).  The AFM cantilever was lowered onto 
the hydrogel surface using the mechanical motor of the AFM, with an average rate of 
approach of 35.4 μm s-1.  The mechanical motor was reversed once the sphere indented the 
gel, as noted by the sudden change in the photodiode signal.  In relaxation experiments, the 
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microsphere was driven into the hydrogel and allowed to relax at the maximum indentation 
(Figure 10).  All measurements were performed in PBS (Sigma).   
 
Figure 10: Example of AFM data.  Cantilever was brought to gel surface (approach) and driven into the gel 
(indentation).  The cantilever was then left at maximum indentation and allowed to relax into the gel (relaxation).  For 
analysis of stiffness, the time axis was converted to indentation by multiplying the time by the rate of approach.  To 
determine the relaxation rate, an exponential curve was fit to the relaxation data.  
Confocal microscopy 
 Cells in gels were fixed in 3.7% formaldehyde after 24 hours of culture.  After 10 
minutes of fixing at room temperature, cells were washed 3x with PBS and then 
permeabilized with 0.01% Triton-X 100 for 3 minutes.  Cells were then washed again 3x 
with PBS and blocked with 10% donkey serum (Millipore) in PBS for 30 minutes.  Cells 
were then incubated with a 1:50 dilution of goat anti-GFAP (Santa Cruz) in blocking buffer 
overnight at 4 ˚C.  After primary antibody incubation, cells were washed with PBS 3x for 
1 hour per wash.  Donkey-anti goat IgG 488 (Invitrogen, 1:100 dilution), CellMask 647 
membrane stain (Invitrogen, 1:1000) and DAPI nuclear stain (1:2500 dilution) were added 
to blocking buffer incubated with the gels for 1 hour at room temperature.  Cells were then 
42 
 
washed 3x with PBS for 1 hour per wash.  Confocal z-stacks were acquired with a Nikon 
TiE microscope equipped with an Andor camera using NIS elements software.  Cells were 
selected randomly in phase contrast to ensure no selection for or against strongly GFAP-
expressing cells occurred. 
 
Analysis of cell morphology and GFAP expression  
 3D reconstructions of astrocyte filaments were generated from confocal Z-stacks using 
Imaris (Bitplane) to obtain quantitative morphological data.  Filament tracing was done on 
the CellMask membrane stain channel to provide information about the morphology of the 
entire cell rather than only the GFAP-positive regions.  Scholl analysis was performed to 
ascertain the amount of astrocyte processes intersecting concentric spheres around the cell 
body [96].  Total additive process length, degree of branching (# process ends / # primary 
processes), weighted process straightness (end-to-end distance over arc-length), and the 
overall cell diameter were calculated for each cell analyzed.  The normalized GFAP 
expression was determined quantitatively from the ratio of the average fluorescence per 
pixel in the cell (cell body and processes) to the average intensity of the gel background.  
This method accounts for any drift in the microscope setup over the seven month duration 
of the experiments.  The cell perimeter was defined from the membrane stain channel using 
ImageJ.   
 
Statistical Analysis 
 Statistical differences in morphology and activation within each gel subcategory 
(collagen, collagen/HA, collagen/HA/Matrigel) were determined using a Student’s t-test.  
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Statistical significance is reported with respect to the best condition (lowest level of 
activation) in each sub-category.  For the overall comparison between the best conditions 
in each subcategory, the best collagen-only control was used as the reference.  P values of 
less than 0.05 were considered statistically significant (*), with P ≤ 0.01 represented with 
**, and P ≤ 0.001 represented with ***. 
 
Compatibility with brain microvascular endothelial cells 
 To test the compatibility of the gels with endothelial cells, immortalized human brain 
microvascular endothelial cells (HBMECs) [78] were grown to confluence on fibronectin-
coated glass chamber slides.  After confluence was achieved, 1.5 mm thick acellular gels 
were formed of top of the monolayers and incubated at 37 °C for 24 hours.  Cells were then 
fixed, permeabilized, and blocked as described above, and incubated with rabbit anti-
human ZO-1 (BD, 1:200 dilution) in blocking buffer overnight at 4 ˚C.  After primary 
antibody incubation, cells were washed with PBS 3x for 1 hour per wash.  Donkey-anti 
rabbit IgG 568 (Invitrogen, 1:100 dilution), and DAPI nuclear stain (1:2500 dilution) were 
added to blocking buffer incubated with the gels for 1 hour at room temperature.  Cells 
were then washed 3x with PBS for 1 hour per wash.  Cells were imaged with a Nikon TiE 





Figure 11:  Schematic of endothelial cells beneath hydrogels for endothelial cell compatibility experiments. 
Results 
Gel characterization 
 Four classes of gels were assessed for astrocyte culture in 3D: HA gels, collagen gels, 
collagen/HA gels, and gels with collagen, HA, and Matrigel.   Although HA is the main 
component of the brain ECM, astrocytes cultured in HA gels were balled up and did not 
exhibit characteristic astrocytic processes (Figure 12) and were not studied further.  This is 
not surprising since the ECM in the brain represents only 10 - 25 % of the total volume and 
HA is a relatively soft material [88, 89].  Although collagen I is not present in the brain, it 
is relatively inert matrix and provides structural support for cell culture.  Matrigel was 
studied as a matrix component for compatibility with endothelial cells in blood-brain 




Figure 12:  Astrocytes in 4 mg mL-1 100% hyaluronic acid (HA) matrix.  Immunofluorescence image, DAPI 
(blue), membrane (purple).  While most of the brain ECM is made up of HA, it represents a relatively small fraction of 
the brain volume (10 - 25%).  Since this HA matrix lacks the fibrous structure provided in the brain by the high density 
of cells, the astrocytes ball up and do not exhibit the characteristic star shaped moprphology with radial processes.  
 The structure of acellular gels was characterized using scanning electron microscopy.  
Collagen-only gels had a wide range of fiber sizes, with diameters from 100 to 1000 nm 
(Figure 13).  Gels containing HA tended to have thicker fibers, in the range of 1 - 5 μm, 
with sheet-like regions characteristic of HA gels [22].  These larger fiber diameters may 
promote more physiological astrocyte morphology since most processes and dendrites in 
the brain have thicknesses within this fiber-size range. 
 
Figure 13: SEM images of acellular gels.  (A)  6 mg mL-1 collagen.  (B)  3 mg mL-1 collagen and 1 mg mL-1 HA.  
(C)  3 mg mL-1 collagen, 1.5 mg mL-1 HA, and 1.5 mg mL-1 Matrigel.   Collagen gels tended to have a very fibrous 
structure with smaller fibers, while the gels containing HA, had a hybrid fiber/sheet structure, with larger fibers.  
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 The mechanical properties of the acellular gels in buffer were characterized using 
atomic force microscopy (AFM).  Force-distance measurements and relaxation curves were 
acquired for all gel compositions.  The Hertz model was used to fit the indentation force 
curve to obtain Young’s modulus values, and relaxation curves were fit to an exponential 
decay curve to determine the relaxation rate.  The stiffness of the gels varied from 150 to 
4000 Pa and the relaxation rates from 0.03 to 0.9 s-1 (Figure 14).   
 
Figure 14:  The modulus and relaxation time constant of the gel matrix influences astrocyte diameter and 
GFAP expression.   (A) Normalized GFAP expression versus gel stiffness. (B) Astrocyte diameter versus gel stiffness.  
(C) Normalized GFAP expression versus gel relaxation rate.  (D) Astrocyte diameter versus gel relaxation rate.  (E) Gel 
compositions and relaxation and stiffness of each gel condition.  Concentrations in mg mL-1, stiffness in Pa, relaxation 
in x10-2 s-1.  
Astrocyte characterization 
 Astrocytes were seeded in a variety of 3D matrices to determine the optimal 
composition for promoting physiological morphology and minimizing GFAP expression 
characteristic of inactive cells.  The cell body and processes were delineated from the cell 
membrane stain.  Cell morphology was determined from analysis of the number of 
processes as a function of distance around the cell body (Scholl analysis), the total additive 
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process length, the degree of branching, the weighted process straightness, and the overall 
cell diameter.   
 In general, fluorescence images of GFAP expression could be classified into two 
categories (Figure 15).  For cells with low levels of GFAP expression in the cell body, the 
fluorescence intensity in the processes was nearly indistinguishable from the background.   
In contrast, cells with bright fluorescence throughout the cell body also tended to show 
enhanced fluorescence in the processes.  Representative images of GFAP expression for 
all gels are shown in Figure 16. 
 
Figure 15: Examples of inactive and active astrocytes in 3D cell culture.  Human fetal derived astrocytes were seeded in 
a gel composed of 2 mg mL-1 collagen, 1 mg mL-1 HA, 1 mg mL-1 Matrigel.  Immunofluorescence images of DAPI (blue) 
and membrane (purple) or DAPI (blue) and GFAP (green).  While both cells express the characteristic branched processes 
of physiological astrocytes, one cell expresses GFAP only in small quantities in the cell body, whereas the other cell 
shows very high expression levels of GFAP throughout the entire cell body and processes, characteristic of activation.  
The cell morphology and level of GFAP expression were quantitatively assessed for astrocytes in collagen gels, 
collagen/HA gels, and gels with collagen, HA, and Matrigel (Figure 17, Figure 18, & Figure 20).  Comparison of the best 
gels from these three classes, including statistical analysis, is presented in Figure 21.   We then analyze the relationship 
between the mechanical properties of the gels and the cell morphology and GFAP expression (Figure 22). 
 GFAP expression was determined quantitatively from the ratio of the average 
fluorescence per pixel in the cell (cell body and processes determined from the cell 
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membrane stain) to the average intensity of the gel background.  In general, for a 
normalized GFAP expression level less than 2, the cells showed low levels of expression 
in the cell body and negligible expression in the processes, whereas for a normalized GFAP 
expression level more than 4, most of the cells showed bright fluorescence in both the cell 
body and processes (Figure 15).  Since GFAP overexpression is associated with astrocyte 
activation, we refer to cells with low levels of GFAP expression (ratio < 2) as inactive, and 
cells with high levels of GFAP expression (ratio > 8) as active.  
 
Figure 16: Membrane and GFAP images used for quantitative analysis.  Membrane stain images were traced using 
ImageJ, and the average pixel intensity in the GFAP images was calculated within the membrane-traced region.  
Membrane stain images have had contrast enhanced for increased clarity.  GFAP images shown are the raw images 
without pseudocolor or any enhancements which were used for the quantitative analysis. 
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 Below we present quantitative analysis of cell morphology and GFAP expression of 
human astrocytes in the four classes of gels.    
 
Astrocytes in HA gels 
While the majority of the brain’s ECM is composed of hyaluronic acid (HA), culturing 
astrocytes in HA alone results in rounded, non-proliferative cells that do not extend 
processes (Figure 12).  Therefore, no further experiments were performed with HA gels. 
 
Astrocytes in collagen gels 
Astrocytes in collagen gels, unlike cells in HA gels, expressed characteristic astrocyte 
processes (Figure 17), but almost all cells expressed high levels of GFAP in both the cell 
body and processes.  In 4 mg mL-1 gels, the average normalized GFAP expression was 4.8, 
whereas in 6 mg mL-1 and 8 mg mL-1 gels, the normalized GFAP expression was 8.4 and 
8.8, respectively  (Figure 17D).  A Scholl plot of the number of processes as a function of 
distance from the cell body (Figure 17E) shows that the average number of primary 
processes ranged from 20 to 30, although the extent of the processes was smallest for the 
8 mg mL-1 gel.   The total process length was 700 - 1600 µm, with the maximum process 
length at a gel concentration of 6 mg mL-1 (Figure 17F).  The degree of branching, defined 
as the number of process ends divided by the number of primary processes, was 3 - 4 for 
all gels (Figure 17G), and the process straightness was 0.91 - 0.93 (Figure 17H) for all gel 
concentrations.  The overall cell diameter decreased from about 140 µm for 4 mg mL-1 
gels, to about 70 µm in the stiffer 8 mg mL-1 gels (Figure 17I).  Overall, the 4 mg mL-1 and 
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6 mg mL-1 collagen gels resulted in astrocytes with longer processes and an overall 
diameter similar to astrocytes in the human brain [7]. 
 
Figure 17: Astrocytes in collagen gels exhibit a star-shaped morphology but high levels of GFAP expression.  
Representative images of astrocytes in collagen gels: (A) 4 mg mL-1, (B) 6 mg mL-1, and (C) 8 mg mL-1 collagen type I.  
Images are maximum intensity projections of confocal z-stacks.  Cells stained for CellMask membrane stain (purple) and 
DAPI nuclear stain (blue). GFAP expression and morphological analysis of astrocytes in collagen gels (N = 8 - 12 cells 
per condition). (D) Activation analysis of the cells shows a high degree of activation at all collagen concentrations. The 
normalized GFAP expression is the ratio of the average fluorescence per pixel in the cell (cell body and processes) to the 
average intensity of the gel background.  (E) Scholl analysis shows the overall morphological characteristics.  (F) Total 
process length, (G) degree of branching, (H) process straightness, and (I) overall cell diameter for astrocytes in collagen 
gels. Data represent mean ± SE.  Statistical significance was determined using a student’s t-test test compared to the 4 
mg mL-1 collagen gel.  *** P ≤ 0.001, ** P ≤ 0.01.  * P≤ 0.05. 
Collagen and HA gels 
 While astrocytes in the collagen-only gels exhibited numerous astrocyte-like processes, 
the high levels of GFAP expression indicate astrocyte activation.  To assess the influence 
of HA on GFAP expression and cell morphology, we seeded astrocytes in collagen/HA 
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gels (Figure 18A-C).  All gels had a total monomer concentration of 4 mg mL-1.  Gels with 
25% HA exhibited a normalized GFAP expression of 1.9, significantly lower than any of 
the collagen gels (Figure 17), whereas cells cultured in gels with 50% collagen and 50% 
HA and showed higher GFAP expression than the corresponding pure collagen gel.  The 
average number of primary processes was about 20 for all three conditions, however, with 
the addition of HA to the matrix the number of processes increased to about 40 at a distance 
of 40 - 50 µm from the cell body (Figure 18E).  The addition of 25 - 50% HA to the matrix 
results in a significant increase in total process length (Figure 18F), although only small 
changes in the degree of branching (Figure 18G), and process straightness (Figure 18H).  The 
overall astrocyte size increased from about 140 µm in collagen gels, to 180 - 210 µm with 




Figure 18:  The addition of HA to collagen gels modulates cell morphology and GFAP expression.  Immunofluorescence 
images of astrocytes in collagen/HA gels with varying amounts of HA.  (A) 100 % collagen HA (4 mg mL-1 collagen), 
(B) 75 % collagen and 25 % HA (3 mg mL-1 collagen + 1 mg mL-1 HA) and (C) 50 % collagen and 50 % HA (2 mg mL-
1 collagen + 2 mg mL-1 HA).  In all cases the total concentration of the gels was 4 mg mL-1.  Images are maximum 
intensity projections of confocal z-stacks.  Cells stained for CellMask membrane stain (purple) and DAPI nuclear stain 
(blue).  Differences in overall cell diameter can be easily seen in these representative images upon the incorporation of 
HA in the hydrogels.  GFAP expression and morphological analysis of astrocytes in gels containing collagen I and HA 
with a total monomer concentration of 4 mg mL-1 (N = 10 - 18 cells per condition).  (D) Normalized GFAP expression 
shows that the incorporation of 25% HA results in very low GFAP expression.  The normalized GFAP expression is the 
ratio of the average fluorescence per pixel in the cell (cell body and processes) to the average intensity of the gel 
background.  (E) Scholl analysis of astrocytes showing overall morphological characteristics.  (F) Total process length, 
(G) degree of branching, (H) process straightness, and (I) overall cell diameter for astrocytes in collagen gels. Data 
represent mean ± SE.  Statistical significance was determined using a student’s t-test test compared to the 3 mg mL-1 
collagen, 1 mg mL-1 HA gel.  *** P ≤ 0.001, ** P ≤ 0.01.  * P≤ 0.05. 
Astrocytes in gels with collagen, HA, and Matrigel 
 While gels containing 75% collagen and 25% HA resulted in low GFAP expression 
and enhanced morphology as compared to collagen only gels, the addition of Matrigel to 
the matrix was necessary to ensure endothelial monolayer survival (Figure 19). Astrocytes in 
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gels with collagen, HA, and Matrigel, similar to cells in collagen/HA gels, showed the 
characteristic star-shaped morphology with multiple radial processes (Figure 20A-D). 
 
Figure 19:  Immortalized human brain microvascular endothelial cells (HBMECs) cultured under hydrogels.  DAPI 
(blue), ZO-1 (red).  HBMECs were grown to confluence in 12 well plates and hydrogels were formed on top of the 
monolayers.  After 24 additional hours of culture, cells were fixed and stained for ZO-1, a tight junctional protein, as 
well as with DAPI nuclear stain.  (A) Confluent monolayer of HBMECs with no gel.  (B) 4 mg mL-1 collagen.  (C) 
Collagen/HA:  3 mg mL-1 collagen + 1 mg mL-1 HA.  (D) Collagen/HA/Matrigel:  3 mg mL-1 collagen, 1.5 mg mL-1 HA, 
and 1.5 mg mL-1 Matrigel.  Confluent monolayers of HBMECs show well defined expression of the tight junction protein 
ZO-1 at cell-cell junctions.  Monolayers in collagen and collagen/HA gels resulted in no visible tight junctions between 
endothelial cells, however, monolayers in gels with collagen, HA, and Matrigel resulted showed well defined cell-cell 
junctions, typical of confluent monolayers in 2D.  The presence of endothelial cell tight junctions is essential for the 
creation of physiologically relevant BBB models. 
 The addition of Matrigel to the matrix strongly influenced GFAP expression (Figure 20E).  
The 2:1:1 (Cn:HA:Mg) gel exhibited a normalized GFAP expression of 3.0, whereas the 
4:1:1, 3:1.5:1.5 and 4:2:2 gels exhibited expression levels of 1.4, 1.2, and 1.2, respectively.  
The Scholl plots (Figure 20F) were similar to those for collagen/HA gels (Figure 18E), with 
about 20 primary processes increasing to a maximum of 35 - 40 process at a distance of 40 
- 50 µm from the center of the cell body.   The total process length (Figure 20G), the degree 
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of branching (Figure 20H), and the overall diameter (Figure 20J) were relatively independent 
of Matrigel concentration.  
 
Figure 20: Gels with collagen, HA, and Matrigel at concentrations greater than 4 mg mL-1 show astrocytic morphology 
and very low levels of GFAP expression.  Representative fluorescence images of astrocytes in gels containing collagen 
(Cn), HA, and Matrigel (Mg).  The ratio X:Y:Z corresponds to the monomer concentration in mg mL-1 (X - collagen, Y 
- HA, Z - Matrigel).  (A) 2 mg mL-1 collagen, 1 mg mL-1 HA, and 1 mg mL-1 Matrigel (2:1:1).  (B) 4 mg mL-1 collagen, 
1 mg mL-1 HA, and 1 mg mL-1 Matrigel (4:1:1).  (C) 3 mg mL-1 collagen, 1.5 mg mL-1 HA, and 1.5 mg mL-1 Matrigel 
(3:1.5:1.5).  (D) 4 mg mL-1 collagen, 2 mg mL-1 HA, and 2 mg mL-1 Matrigel (4:2:2).  Images are maximum intensity 
projections of confocal z-stacks.  Cells stained for CellMask membrane stain (purple) and DAPI nuclear stain (blue).  
GFAP expression and morphological analysis of astrocytes in gels containing collagen I, HA, and Matrigel (N = 22 - 28 
cells per condition. (E) Activation analysis of the cells shows that the incorporation of HA and Matrigel results in fewer 
cells expressing GFAP. The normalized GFAP expression is the ratio of the average fluorescence per pixel in the cell 
(cell body and processes) to the average intensity of the gel background.  (F) Scholl analysis of the astrocytes shows 
overall morphological characteristics.  (G) Total process length, (H) degree of branching, (I) process straightness, and (J) 
overall cell diameter for astrocytes in collagen gels.  Data represent mean ± SE. Statistical significance was determined 
using a student’s t-test test compared to the 3 mg mL-1 collagen, 1.5 mg mL-1 HA, 1.5 mg mL-1 Matrigel gel. *** P ≤ 
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0.001, ** P ≤ 0.01.  * P≤ 0.05.   Comparison of astrocytes in collagen, collagen/HA, and 
collagen/HA/Matrigel 
 To highlight the influence of matrix composition on astrocyte morphology and GFAP 
expression, we compare the best results for each of the three classes of gel (Figure 21): (1) 4 
mg mL-1 collagen, (2) 3 mg mL-1 collagen + 1 mg mL-1 HA, and (3) 3 mg mL-1 collagen, 
1.5 mg mL-1 HA, and 1.5 mg mL-1 Matrigel.   The latter two conditions had 
indistinguishable cell morphologies compared to the best collagen-only gel with diameters 
larger than 200 µm, total process lengths > 3800 µm, and a degree of branching > 4.   The 
normalized GFAP expression for the best collagen/HA and collagen/HA/Matrigel gels 




Figure 21: Comparison of the best conditions of collagen gels, collagen/HA gels, and collagen/HA/Matrigel gels.  
Collagen:  4 mg mL-1 collagen, collagen/HA:  3 mg mL-1 collagen + 1 mg mL-1 HA, and collagen/HA/Matrigel:  4 mg 
mL-1 collagen, 2 mg mL-1 HA, and 2mg mL-1 Matrigel.  (A) Normalized GFAP expression.  The normalized GFAP 
expression is the ratio of the average fluorescence per pixel in the cell (cell body and processes) to the average intensity 
of the gel background.  (B) Scholl analysis of the astrocyte processes.  Morphological parameters for astrocytes in gels: 
(C) total process length, (D) degree of branching, (E) process straightness, and (F) overall cell diameter. Data represent 
mean ± SE.  Statistical significance was determined using a student’s t-test test compared to the 4 mg mL-1 collagen gel.  
*** P ≤ 0.001, ** P ≤ 0.01.  
 
GFAP expression, cell morphology, and gel stiffness 
 The stiffness and relaxation rate of the gels also plays a role in modulating cell 
morphology (Figure 22).   The elastic modulus and shear modulus of collagen gels increases 
with increasing monomer concentration, but is also dependent on the gel microstructure 
which, in turn, is dependent on experimental conditions such as gelation temperature and 
pH [97, 98].  For collagen gels with concentration from 3 mg mL-1 to 9 mg mL-1 the elastic 
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modulus has been reported to increase from about 500 Pa to about 12 kPa and the shear 
modulus from about 200 Pa to about 5 kPa (an E/G ratio of 2.25) [98].   Using AFM 
indentation, we obtain elastic modulus values of 190 Pa for 2 mg mL-1 collagen and 3800 
for 8 mg mL-1 collagen, in the range reported in the literature.  
 
Figure 22: The modulus and relaxation time constant of the gel matrix influences astrocyte diameter and GFAP 
expression.  (A) Normalized GFAP expression versus gel stiffness. (B) Astrocyte diameter versus gel stiffness.  (C) 
Normalized GFAP expression versus gel relaxation rate.  (D) Astrocyte diameter versus gel relaxation rate.  (E) Gel 
compositions and relaxation and stiffness of each gel condition.  Concentrations in mg mL-1, stiffness in Pa, relaxation 
in x10-2 s-1.  
 No clear correlation was observed between the measured gel stiffness and GFAP 
expression, although the lowest levels of GFAP expression were generally found for gel 
stiffnesses of 1000 - 1500 Pa (Figure 22A).  The overall cell diameter shows a maximum of 
about 220 µm corresponding to gels with stiffness in the range from 900 - 1500 Pa (Figure 
22A).  The maximum in cell diameter occurs at a stiffness that is somewhat larger than the 
bulk shear modulus of 200 - 300 Pa reported for human, rat, and pig brain [99, 100], 
however, our gels have a very low density of cells compared to brain tissue.  GFAP 
expression had a very strong correlation with the gel relaxation rate (Figure 22C), which is 
related to the stress relaxation modulus.  The minimum in GFAP expression was observed 
58 
 
at a relaxation rate of 0.1 - 0.2 s-1.   The overall cell diameter also showed a maximum as a 
function of the gel relaxation rate (Figure 22D).   
 These results indicate that the mechanical properties of gels play an important role in 
modulating the morphology of astrocytes and their expression of GFAP.  In soft gels, the 
matrix is easily deformed, however, the low stiffness and relaxation rate reduces the 
traction forces necessary for extending new processes.  In stiff gels, there is sufficient 
traction for new processes but it is difficult to deform the matrix.  Therefore, it appears 
there is an optimum range of stiffness and relaxation rate required for astrocytes to adopt a 
physiological morphology. 
 
Compatibility with endothelial cells 
 To test the compatibility of these gels with brain microvascular endothelial cells, gels 
were formed on top of confluent monolayers of HBMECs.  After 24 hours, HBMECs under 
collagen and collagen/HA gels showed low expression levels of the tight junction protein 
ZO-1 (Figure 19).  In contrast, HBMEC monolayers under gels with collagen, HA, and 
Matrigel showed ZO-1 expression and localization at the cell-cell junctions typical of 
monolayers in 2D culture (Figure 19) [93]. The presence of endothelial cell tight junctions is 
essential for the creation of physiologically relevant BBB models, indicating that these in 






 Astrocytes extend highly ramified processes that make contact with blood vessels, 
synapses, nodes of Ranvier, and other neuronal and non-neural elements, placing them in 
a unique position to control brain metabolism by providing an interface between the 
circulation and the brain parenchyma. How they perform this homeostatic function is not 
well understood. Much of our knowledge about the functions of these cells comes from 
studies in mice and rats. Although human astrocytes are larger and more diverse in their 
structure [7], much less is known about their physiological characteristics. Given the 
limitations associated with analysis of cellular properties in the intact human CNS, in vitro 
studies provide crucial insight to the characteristics of these cells, necessitating 
development of conditions that retain their in vivo properties. Here we examined how 
various culture conditions influence the morphological maturation of astrocytes and their 
reactive state and define a 3D matrix that enables vigorous process formation by astrocytes 
but retains their quiescent state.  
 GFAP is a widely used biomarker of reactive gliosis, providing a ready measure of the 
transformation of astrocytes in different pathological conditions. In our studies, the average 
normalized GFAP expression ranged from < 2 (1.4, 1.2, 1.2, and 1.9) for three Cn/HA/Mg 
gels and one Cn/HA gel, to 8 - 10 for two collagen gels and one Cn/HA (8.4, 8.4, and 8.7).  
Cells in the 4 mg mL-1 collagen gel, and the 2:1:1 (Cn:HA:Mg) gel, showed intermediate 
values of GFAP expression (4.8 and 3.0, respectively).  For GFAP ratios < 2, fluorescence 
images of cells generally showed weak expression in the cell body and negligible 
expression in the processes.  In contrast, cells with GFAP ratios > 8 showed high intensity 
in both cell body and processes.  The maximum increase in GFAP expression between 
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conditions is approximately 8-fold.  A 7.5-fold increase in the gene encoding for GFAP 
has been reported for cortical astrocytes in a mouse model following activation induced by 
transient ischemia [86].   Taken together, these results suggest that astrocytes in 3D gels 
with low GFAP ratios are quiescent, whereas cells with high GFAP ratios are activated. 
 Although collagen gels are commonly used as a matrix for 3D cell culture [101, 102], 
astrocytes in collagen gels are smaller, less branched, and exhibit high levels of GFAP 
expression in the cell body and processes, characteristic of activated cells (Figure 17). 
Mixed collagen/HA gels were investigated as a matrix for astrocytes since HA is the major 
component of brain ECM.  In addition, astrocytes express CD44, a receptor for HA, and 
hence the addition of HA to the matrix is expected to result in more physiological 
morphology [103].  The addition of HA results in an increase in the total process length, 
degree of branching, and overall cell diameter (Figure 18).  The average normalized GFAP 
expression in gels with 75% collagen and 25% HA (4 mg mL-1 collagen + 1 mg mL-1 HA) 
was 1.9, significantly lower than in the corresponding 4 mg mL-1 collagen gel, where the 
normalized GFAP expression was 4.8.  In gels with 50% collagen and 50% HA the 
normalized GFAP expression was 8.9 ± 1.3, similar to the higher collagen concentrations 
(Figure 18).  Since cells in pure HA-crosslinker gels are rounded and do not exhibit radial 
processes, the increase in GFAP expression in 50% collagen - 50% HA gels can be ascribed 
to the increased HA concentration.  The PEG-based crosslinker used in the HA-based gels 
is unlikely to have a significant influence on astrocyte activation, since PEG-based 




Gels with collagen, HA, and Matrigel exhibit similar morphological characteristics, 
typical of astrocytes in the human brain, and very low levels of GFAP expression (Figure 
20).   The 4:1:1, 3:1.5:1.5 and 4:2:2 gels exhibited expression levels of 1.4, 1.2, and 1.2, 
respectively, suggesting a quiescent or unactivated state.  While laminin is known to 
promote neurite outgrowth [92, 105], and to exist in small quantities in the developing and 
injured brain [92], it is very rarely added to 3D matrices for brain cell culture.  Matrigel, 
which is primarily composed of laminin, has been shown to promote endothelial cell 
growth and tubulogenesis in vitro [106].  
 Astrocytes imaged in collagen/HA and collagen/HA/Matrigel gels were somewhat 
larger (≥ 200 µm diameter) compared to human protoplasmic astrocytes in vivo, which are 
approximately 150 μm in diameter [7, 25].   Detailed comparison of the size and 
morphology of astrocytes in the human brain is complicated by the fact that images are 
obtained from tissue sections from patients with epilepsy or brain cancer and use GFAP 
staining rather than a membrane stain [7].  In addition, human astrocytes in the brain tend 
to extend longer processes during development, which then retract into independent 
astrocyte domains as the cells are constrained by their neighbors [62].  In the experiments 
reported here, the astrocytes were seeded at a much lower density than in the brain for 
single-cell imaging, and hence were not confined by interactions with their neighbors.  The 
degree of branching observed in these experiments was very similar to the degree of 
branching observed in astrocytes in the mouse optic nerve [107].   
 Comparison of cell morphology and GFAP expression (Figure 23) suggests a correlation 
between cell morphology and activation.  In general, cells with low GFAP expression had 




Figure 23: Correlation between normalized GFAP expression and morphological parameters.  In general, low levels of 
GFAP expression are correlated with large diameter (> 180 µm), long total process length (>2000 µm), and high degree 
of branching (> 4).Astrocytes in gels with collagen, HA, and Matrigel were found to have nearly 
indistinguishable morphologies, likely due to the fact that all four conditions assayed had 
very similar stiffnesses (Figure 22).  However, GFAP expression was significantly 
upregulated in 2:1:1 (Cn:HA:Mg) gels.  Since this gel matrix had a much lower relaxation 
rate (which corresponds to slower stress relaxation) compared to all of the other conditions 
in this category (Figure 22), it is possible that the mechanical properties of this gel were 
responsible for the increased activation response. This effect likely also explains the 
dramatic difference in activation between the two gels containing both collagen and HA.  
The very low relaxation rate measured in the 2 mg/mL collagen, 2 mg/mL HA gel likely 
explains the increased GFAP expression of astrocytes in this gel.  From these experiments, 
it seems that sufficiently low (<0.1 s-1) or high (>0.2 s-1) gel relaxation rates results in 
increased GFAP expression. 
Astrocytes are known to be an essential component of the blood-brain barrier, 
participating in BBB repair and maintenance, producing proteins, such as GDNF and 
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bFGF, that enhance BBB tightness, and regulating water, ion, and amino acid homeostasis 
[4, 6].  While many in vitro models of the human BBB incorporate astrocytes, most of these 
models involve the culture of astrocytes in 2D, and often do not include contact with 
endothelial cells [23, 71, 72].  These astrocytes tend to be spindle-shaped and almost 
always express markers associated with astrocyte activation [18].    Through this 
exploration of hydrogel compositions, we developed a new in vitro platform for the study 
of the blood-brain barrier may promote a deeper understanding of how astrocytes influence 
the formation and function of the BBB, and reveal new approaches for limiting damage 




 The morphology and level of GFAP expression in human astrocytes is strongly 
dependent on the composition and mechanical properties of the 3D microenvironment.  To 
test the hypothesis that astrocytes cultured in a 3D matrix that provides structural support 
and appropriate extracellular matrix factors will recapitulate the characteristic star-shaped 
morphology and low levels of GFAP expression typical of quiescent astrocytes, we 
cultured human astrocytes in four classes of gels: HA gels, collagen gels, collagen/HA gels, 
and gels composed of collagen, HA, and Matrigel.  Astrocytes cultured in gels composed 
of collagen, HA, and Matrigel exhibited a highly branched morphology, typical of their 





Chapter 4: Influence of astrocyte activation on glioblastoma progression 
in vitro. 
Abstract 
 Glioblastoma is the deadliest form of brain cancer, with over 10,000 new cases 
diagnosed every year.  Typical survival times for glioblastoma patients, even with surgical, 
chemotherapeutic, and radiation-based treatments, remain very low despite advances in 
treatment.  In brain cancers, astrocytes, which comprise approximately 50% of the cells in 
the brain, become activated, resulting in a layer of reactive astrocytes surrounding the 
tumor.  This process of reactive gliosis, which involves the secretion of growth factors and 
cytokines, helps repair injury in the brain, but also plays a role in disease progression.  In 
this study, we investigated the effects of human astrocytes on primary glioblastoma 
progression, by measuring effects on proliferation, invasion, and adhesion in 2D, as well 
as measuring the effects of astrocytes on tumor growth in a novel, physiologically relevant 
3D spheroid assay.  In addition, we investigated the effects of astrocyte activation 




Glioblastoma and Brain Metastatic Cancer: 
 In 2010, approximately 140,000 people in the United States were living with a 
malignant brain tumor.  The median survival time for malignant gliomas, which account 
for 80% of all malignant brain tumors, is approximately 15 months, a figure which has 
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remained stagnant over the last 40 years [108-111]. Treatment for malignant gliomas 
typically involves surgical resection followed by chemotherapy or radiation therapy [112, 
113]. Even with treatment, however, less than 10% of patients survive five years after 
diagnosis [29, 113-115].  
 
 
Astrocyte Influence on Brain Tumor Proliferation and Invasion 
 In the brain tumor microenvironment, tumors are surrounded by reactive glia [42, 116]. 
Current brain cancer therapeutics focus only on the cancer cells, ignoring the effects of 
cancer on the rest of the brain and vice versa. Astrocytes and microglia, which compromise 
50 and 10-15% of the cells in the brain, respectively, are activated in the presence of cancer 
cells, releasing growth factors and inflammatory cytokines [116]. Accumulating in vitro 
evidence shows that these factors secreted by reactive astrocytes and microglia enhance 
tumor progression by promoting proliferation, invasion, and immune evasion [34, 35, 116]. 
Compounding this effect is the fact that astrocytes and microglia are known to become 
activated in response to chemotherapy and radiotherapy in vivo [117-119], which may 
cause enhanced growth of the surviving cells after treatment. In these experiments, we 
aimed to address these issues by determining which glial activation attenuating therapeutics 
have the strongest effect on reducing glioma progression. 
 Reactive astrocytes have been found in vitro to enhance proliferation and invasion of 
glioma cells up to 5-fold.  This is caused by the secretion of growth factors and 
inflammatory cytokines such as IL-6, EGF, IGF-1, and GDF-15 [116].  All of these factors 
are expressed in significantly decreased quantities in quiescent astrocytes than in reactive 




Current In Vitro Models of Brain Cancer 
  As shown in Figure 24, several types of in vitro platforms can be used to investigate 
various aspects of cancer progression, such as invasion, metastasis, and angiogenesis [120].  
In glioblastoma research, transwell and spheroid-based platforms are widely used to study 
tumor invasion.  In transwell invasion assays, cancer cells are typically plated in or on top 
of a gel matrix (most often Matrigel) in the apical compartment with a chemoattractant in 
the basolateral compartment (typically FBS [120] but also often astrocytes [40, 109] or 
microglia [46, 121]) to observe either the effects of various chemoattractants on invasion, 
or the influence of drug or gene therapy on invasion [120].  These platforms provide a good 
system to study individual cell invasion, while spheroid-based platforms are best to study 
bulk tumor growth and migration.  Spheroids of glioblastoma cells are often formed in 
suspension culture, though for some cell types, or to obtain a more uniform spheroid size, 
other spheroid formation methods, such as the hanging drop technique, are also used [120].  
After spheroids are formed, they are either seeded into low attachment plates in media 
[122, 123], into hydrogels such as collagen [124] or Matrigel [125] or into rodent brain 
slices [126].  While assays performed in media result in faster spheroid growth, they are 
less physiological in recapitulating the brain microenvironment, and only change in 
spheroid size can be observed.  In hydrogel or brain slice invasion assays, however, both 
bulk tumor growth and invasion away from the bulk tumor can be observed [125, 126].  
Coculture is often utilized in spheroid platforms to create a more physiological 
environment.  Coculture spheroids of glioblastoma cells and microglia [124] and of 
glioblastoma cells and astrocytes [123] have been used to study the effects of glia on 
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glioblastoma progression, however, these homogeneous spheroids lack the physiological 
configuration of cells in the tumor microenvironment [42]. 
 
 
Figure 24:  Types of in vitro platforms used to study cancer progression in human cells. 
 
Astrocyte Activation Attenuating Drug Therapy 
 While several drugs have previously been shown to reduce glial activation in rodent 
models, none of these therapeutics have been applied to reducing cancer induced 
activation, or used in conjunction with chemotherapeutics to reduce cancer invasiveness 
and proliferation. Ibudilast, which has been approved for treatment of asthma in Japan 
[127] and is known to cross the blood-brain barrier, has been shown to reduce astrocyte 
and microglial activation in MCAO [128] and codeine-induced hyperalgesia [129] in 
rodent models, and is currently in clinical trials for treatment of opioid and 
methamphetamine dependence, MS, and ALS [130]. Laquinimod, which also crosses the 
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blood-brain barrier, reduces astrocyte activation in response to various inflammatory 
cytokines [131], and is currently in clinical trials for the treatment of Huntington’s Disease 
and MS [64]. 
 
Materials and Methods: 
Cell culture 
 Human fetal-derived astrocytes as well as patient-derived primary glioblastoma cells 
(GBM 612 and GBM 1A) were acquired from the laboratory of Dr. Alfredo Quinones-
Hinojosa.  Primary human fetal-derived astrocytes were obtained as described previously 
[22-24], following approval by the Johns Hopkins University Institutional Review Board.  
Intraoperative human central nervous system tissues, gestational weeks 19 - 21, which were 
obtained following written informed consent for clinical procedures, were used to generate 
the fetal-derived astrocytes for this research as they are considered pathological waste.   
Neural cells were cultured first in suspension as neurospheres in low-attachment flasks 
using DMEM/F12 (Sigma) medium with 2% B27 supplement (GIBCO), 1% penicillin-
streptomycin (Invitrogen), 20 ng mL-1 of EGF (Peprotech) and bFGF (Peprotech), 10 ng 
mL-1 of LIF (Millipore), and 5 µg mL-1 of heparin (Sigma). In order to obtain astrocytes, 
neurospheres were mechanically dissociated and single cells were plated on tissue culture 
flasks in DMEM/f12 medium (Sigma) supplemented with 10% fetal bovine serum (Sigma) 
and 1% penicillin-streptomycin (Invitrogen).  GFP-expressing glioblastoma cell lines 
GBM 1A and GBM 612 were cultured either adherently on laminin-coated tissue culture 
flasks, or in suspension in non-adherent NUNC tissue culture flasks.  Cell culture media 
for both glioblastoma cell lines consisted of DMEM/f12 medium (Sigma) supplemented 
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with 2% B27 supplement (Invitrogen), 1% antibiotic-antimycotic (Invitrogen), EGF 
(Peprotech), and bFGF (Peprotech) both at a concentration 20 ng mL-1. 
 
Proliferation Assay 
 GFP-labeled glioblastoma cells were seeded into multiwell plates at a concentration of 
5000 cells/cm2.  After cells were allowed to adhere for 24 hours, the culture media was 
replaced with either unsupplemented media (DMEM/f12, 1% A-A), astrocyte conditioned 
media (prepared by incubating astrocytes in unsupplemented media for 72 hours prior to 
filtering and transferring to glioblastoma cells), or 2500 astrocytes/cm2 in unsupplemented 
media.  Following 48 hours of treatment under these conditions, cells were fixed with 3.7% 
formaldehyde and stained with DAPI to visualize nuclei. To obtain an accurate count of 
only the glioblastoma cells, colocalization of GFP and DAPI was required for a cell to be 
counted.  Three 10x epifluorescence images were acquired per well, and the total amount 
of glioblastoma cells per field was counted. 
 
Transwell Invasion Assays 
 For studies on the influence of the location of astrocytes on tumor invasion, four 
conditions were assayed (Figure 25).  No astrocytes were present in the control condition.  
In order to assay whether the astrocytes enhanced invasion through chemoattraction or 
through an increase in general motility, astrocytes were placed in the gel with the 
glioblastoma cells (astrocytes top) or plated in the basolateral chamber of the transwell 
(astrocytes bottom).  In addition, in order to assay whether direct contact between 
astrocytes and glioblastoma cells is necessary for astrocytes to secrete factors that promote 
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invasion, media was pre-conditioned with astrocytes and cancer cells (unsupplemented 
media was added to a 50:50 culture of astrocytes and glioblastoma cells and incubated for 
48 hours) (ACCM).  For the “astrocytes bottom” condition, astrocytes were plated at a 
concentration of 2500 cells/cm2 in the basolateral chamber of the 24-well Transwell 
(Corning) dish 48 hours prior to seeding glioblastoma cells.  For all conditions other than 
“astro top,” 30,000 cells/well were seeded in 100 µL of 3 mg mL-1 growth factor reduced 
Matrigel (Corning) into the apical compartment of the Transwell dish.  In the “astrocytes 
top” condition, 2500 astrocytes were also seeded into the Matrigel in the apical chamber.  
After the gels were allowed to set for 30 minutes at 37 ºC, 600 µL of unsupplemented 
media was added to the basolateral chamber of the Transwell, and 50 µL was added to the 
apical chamber on top of the gel.  In the ACCM condition, 600 µL of astrocyte-glioma 
conditioned media was added to the basolateral chamber, with 50 µL of unsupplemented 
media added on top of the gel.  After 72 hours of incubation, the wells were fixed in 3.7% 
formaldehyde and stained with DAPI.  Confocal fluorescence imaging was used to 
accurately image which cells were above or below the 10 µm thick transwell membrane.  
Three 3x3 large image scans at 40x were obtained per well, and all cells co-expressing GFP 
and DAPI were counted towards the total cells per field.   
 
Figure 25: Schematic of transwell invasion assay conditions. 
 For the studies on the influence of activation-inhibiting therapeutics on glioblastoma 
invasion, the experiments were run for 48 hours, and 100,000 glioblastoma cells were 
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seeded per well, in order to accommodate short half-lives of drugs at 37 ºC.  Astrocytes 
were plated in the basolateral chamber of half of the wells, and 100 µM Ibudilast (Sigma) 
or 5 µM Laquinimod (MedChemExpress) was added to the unsupplemented media in both 
the apical and basolateral chambers.  After 48 hours of incubation, the wells were fixed in 
3.7% formaldehyde and stained with DAPI.  Confocal fluorescence imaging was used to 
accurately visualize which cells were above or below the 10 µm thick transwell membrane.  
Three 3x3 large image scans at 40x were obtained per well, and all cells co-expressing GFP 
and DAPI were counted towards the total cells per field. 
 
Spheroid Adhesion Assays 
 Spheroids of glioblastoma cells were grown in suspension until they reached an average 
size of 50 µm in diameter.  The flask of spheroids was then split into four conditions: 
control, astrocyte-conditioned media (ACM), astrocyte-glioma conditioned media 
(ACCM), and coculture.  These conditions, respectively, contained (1) unsupplemented 
media, (2) astrocyte-conditioned media as defined above, (3) ACCM as defined above, and 
(4) approximately 50 astrocytes/spheroid in unsupplemented media, and were plated in a 
12-well glass bottom plate.  Spheroids were cultured for an additional 72 hours prior to 
washing once gently to remove any non-adherent spheroids, and then imaging with live 
cell fluorescence microscopy.  Three 10x images were acquired per well, and the total 




Spheroid Invasion Assays 
 Spheroids of glioblastoma cells were grown in suspension until they reached an average 
size of 50-100 µm in diameter.  The flask contents were then split in two, and 
approximately 50 astrocytes/spheroid in unsupplemented media were added in the 
experimental condition, while the control was cultured in unsupplemented media.  The 
astrocytes were allowed to attach to spheroids for 48 hours in media prior to being seeded 
in gels.  While initially the optimized hydrogel (Chapter 3) containing collagen, HA, and 
Matrigel was used, this resulted in very slow growing spheroids, and was changed to a gel 
of 2.5 mg/mL collagen (Corning) and 0.5 mg/mL growth factor reduced Matrigel 
(Corning).  Gels were allowed to set for 30 minutes prior to unsupplemented media being 
added on top of the gels.  Spheroids were then immediately transferred to the live cell 
chamber of a microscope, and imaged with phase contrast and fluorescence microscopy 
for 48-72 hours.  After the live-cell imaging was complete, spheroids were fixed in 3.7% 
formaldehyde, permeabilized with 0.01% Triton-X, and stained for GFAP expression.  
Spheroids were then imaged with confocal fluorescence microscopy. Schematic of these 
experiments is shown in Figure 26. 
 




Drug Permeability Study 
 In order to determine the permeability of Ibudilast across an endothelial monolayer, 
MDCK II cells were plated to confluence on a transwell membrane.  Ibudilast (100 µM in 
0.1% DMSO in HBSS) was added to the apical chamber of the transwell dish and allowed 
to pass through the monolayer for 15 minutes.  The input and final concentrations, as well 
as known concentrations to generate a calibration curve, were determined with HPLC as 
previously described [132]. 
 
Preliminary In Vivo Studies 
 Glioblastoma 1A cells were detached from culture with accutase and resuspended in 
ice cold PBS. Thirty 5 week-old athymic nude male mice were injected intracranially with 
105 cells per mouse to form glioblastoma tumors.  After the tumors were allowed to grow 
for seven days, mice were randomly split into three groups: control (vehicle, 5% ethanol 
in PBS), low dose (2 mg/kg Ibudilast), and high dose (10 mg/kg Ibudilast).  Mice were 
injected with Ibudilast or vehicle intraperitoneally every day for 7 days (Figure 27).   
 
Figure 27: Schematic of preliminary in vivo timeline 
 Mice were perfusion fixed with 10% formalin following the final day of drug 
treatments, and brains were cryosectioned into 12 µm slices.  Sections were stained for 
DAPI to visualize all brain nuclei, human nuclei (Millipore anti-human nuclei), to visualize 
only tumor cells, and GFAP (Santa Cruz, Goat anti-GFAP) to visualize astrocyte 
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activation.  Whole brains were imaged utilizing the large image stitching functions on a 
Nikon TiE epifluorescence microscope. Activation range was analyzed by measuring 
profile plots across tumors in ImageJ.  Profile plots of the human nuclei channel were used 
to determine the location of the tumor margins, while profile plots in the same location on 
the GFAP channel were used to determine the activation margin around the tumors. 
 
Results and Discussion 
Influence of Astrocytes on GBM 612 Proliferation, Invasion, and Adhesion 
 The effect of astrocytes on GBM 612 cell proliferation, invasion, and adhesion was 
assayed under various conditions (Figure 28).  Both astrocyte coculture and astrocyte-
conditioned media were utilized to determine the effect of cell contact on glioblastoma 
progression.  In addition, to determine the influence of astrocyte location on glioblastoma 
invasion, astrocytes were both plated with the cancer cells in the apical chamber, and in 
the basolateral chamber of a transwell.  It was observed that astrocyte-conditioned media 
had no effect on GBM 612 cell proliferation, while coculture with astrocytes had a small 
but statistically significant negative effect on proliferation (Figure 28A).  This is likely due 
to the fact that astrocytes consume media resources such as glucose, which resulted in the 
glioblastoma cells dividing at a slower rate.  Transwell invasion of GBM 612 cells, 
however, was greatly enhanced by astrocytes in all configurations (Figure 28B).  Astrocyte 
coculture, both above and below the transwell membrane, resulted in the greatest 
enhancement.  Six-fold to 15-fold enhancements in invasion were observed in the various 
conditions, much higher than the 2 to 5-fold enhancements typically observed with 
astrocyte coculture [116].  In addition, no statistically significant difference was observed 
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between the conditions containing astrocytes above and below the transwell membrane, 
indicating that astrocytes mainly promote invasion due to an overall increase in motility, 
as opposed to acting as a chemoattractant.  Spheroid adhesion was studied as well, as cancer 
cell adhesion is associated with invasion and metastasis potential [133].  While it was 
expected that astrocytes in coculture would surround the spheroids (Figure 29) and promote 
adhesion to a greater degree than ACM, all three astrocyte involving conditions (ACM, 
ACCM, and coculture) provided roughly equal enhancement of adhesion over the control 
(Figure 28C).  
 
Figure 28: Influence of astrocytes on glioblastoma 612 cell proliferation (A), invasion (B), and adhesion (C) in vitro.  
While coculture had a negative effect on proliferation, it strongly promoted invasion and adhesion of glioblastoma 612 
cells. Data represent mean ± SE. Statistical significance was determined using a student’s t-test. *** P ≤ 0.001, ** P ≤ 
0.01.  * P≤ 0.05. 
 
Figure 29: Spheroid adhesion to glass bottom surface.  GFAP-expressing astrocytes (purple) surround the GFP-




Spheroid Growth in GBM 612 and GBM 1A Cells 
 
Figure 30: GBM 612 spheroid invasion.  (A) Confocal 3D z-stack reconstruction of GBM 612 spheroid (GFP labeled – 
green) surrounded by active, GFAP-expressing astrocytes (purple). (B) Single confocal slice showing that no astrocytes 
(purple) were able to penetrate beyond the surface of the GBM spheroid. (C) Graph of the fraction change in radius after 
48 hours in hydrogel. Data represent mean ± SE. GBM 612 cells were used for preliminary spheroid 
invasion assays.  It was found that while astrocyte coculture had a very strong effect on 2D 
invasion and on spheroid adhesion, very little, if any, effect was observed in 3D spheroid 
growth (Figure 30C).  It should be noted, however, that several tumor cell escape events (in 
which a tumor cell detaches from the spheroid and migrates alone elsewhere in the gel) 
were observed in the coculture, but not in the GBM alone condition.  In both conditions, 
the spheroids expanded rapidly over the first six hours in culture, and remained at 
approximately the same size for the remainder of the experiment (Figure 33), making the 
GBM 612 cells a poor choice for further testing and for drug screening applications. 
 Confocal microscopy of the coculture spheroids, however, showed that the astrocytes 
on the spheroids remained on the surface of the spheroid for the duration of the experiment 
(Figure 30A, B), recapitulating what has been observed with astrocytes surrounding tumors 
in vivo [16, 42, 46].  While homogeneous spheroids of glioblastoma cells and astrocytes 
have been previously utilized for drug screening [123], these heterogeneous spheroids 




Figure 31: GBM 1A spheroid invasion.  Data represent mean ± SE. 
 
 GBM 1A cells were utilized for further spheroid growth assays as they are known to 
be more invasive cells than the GBM 612 cells in vivo.  Over the first 30 hours of a 48 hour 
experiment (GBM alone gel began to dry out after this time, making comparison difficult), 
the spheroids cocultured with astrocytes on the surface tended to grow, while the GBM 1A 
spheroids tended to stay the same size or shrink over the same time period. 
 
Astrocyte Activation Attenuating Therapy on GBM 1A Cells 
 It has been demonstrated that Laquinimod [131] and Ibudilast [127, 128] are capable 
of reducing astrocyte activation.  In these experiments, the invasiveness of glioblastoma 
1A cells was assayed in a transwell invasion assay, incorporating both astrocyte coculture 
and drug therapy (Figure 32).  As it was shown in experiments with the GBM 612 cells that 
astrocyte location did not have a significant impact on invasion, all astrocytes were seeded 
in the basolateral chamber to be most analogous to previous studies [40, 42, 45].  It was 
found that astrocytes enhanced invasion approximately 3-fold as compared to monoculture 
controls.  This is similar to the 2 to 5-fold enhancements by astrocytes typically observed 
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previously [40, 45, 47].  It was found that treatment of glioblastoma cells in coculture with 
astrocytes with Laquinimod or Ibudilast resulted in a number of invasive cells statistically 
indistinguishable from the control with no astrocytes, and the astrocytes treated with 
Laquinimod resulted in significantly lower invasion than glioblastoma cells cultured with 
astrocytes and no treatment (Figure 32B).  In addition, it was found that the combination of 
the two therapies did not result in decreased invasion as opposed to the individual therapies, 
and was significantly larger than Laquinimod alone.  This could be caused by several 
mechanisms, as the two drugs may work through competing biological mechanisms, or 
may aggregate, which could decrease cellular uptake.   
 
Figure 32: Influence of astrocyte coculture and activation attenuating therapy on glioblastoma 1A invasion. Figure 32A 
shows the amount of cells able to invade across the transwell membrane in all conditions assayed, while Figure 32B 
shows the astrocyte and drug combinations as compared to the untreated control with no astrocytes.  Data represent mean 
± SE. Statistical significance was determined using a student’s t-test test. ** P ≤ 0.01.  * P≤ 0.05.    
 In addition, the results indicate that Laquinimod has a positive effect on the invasion 
of glioblastoma 1A cells cultured alone (Figure 32A).  The mechanism of this should be the 
topic of further study, and these results imply that in the presence of astrocytes, 
Laquinimod not only inhibits the effect of astrocytes on glioblastoma invasion, but actively 
reduces invasion as compared to controls.  Ibudilast, however, had no effect on invasion in 




Comparison of GBM 612 and GBM 1A Cells 
 While the GBM 612 cells showed initial promise in vitro in the 2D invasion and 
spheroid adhesion experiments, their lack of growth after the first 6 hours in 3D (Figure 
33), made them a poor choice for future studies.  The GBM 1A cells invaded to a greatly 
decreased degree in a transwell assay under the influence of astrocytes, but it was found 
that the spheroids continued to grow for the entire duration of the 48 hour spheroid 
experiments (Figure 33).  Since both the 2D and 3D assays involve movement through 
extracellular matrix components, it is possible that the rate-limiting factor for the GBM 1A 
invasion is the pore size of the transwell membrane.  Given that glioblastoma invasion in 
vivo tends to involve migration along white matter tracts [134] and along blood vessels 
[135], this lack of ability to migrate through 8 µm pores should not be relevant in translation 
to in vivo testing. 
 




Preliminary In Vivo Studies  
 Through in vitro permeability experiments utilizing HPLC, we were able to determine 
the permeability of Ibudilast through MDCK II cells to be 5 x 10-5 cm/s, which is consistent 
with successful delivery to the brain [69].  To determine the effect of Ibudilast treatment 
on astrocyte activation surrounding glioblastoma tumors, brain sections were stained for 
both tumor nuceli (Figure 34A) and GFAP expression (Figure 34B).   
 
Figure 34: Analysis of Ibudilast treatment on astrocyte activation surrounding glioblastoma tumors.  (A) DAPI (blue) 
and human nuclei (green) in mouse brain hemisphere.  (B) DAPI (blue) and GFAP (red) in mouse brain hemisphere.  (C) 
Zoomed-in image of tumor margin surrounded by reactive astrocytes.  (D) Analysis of activation margins around tumors.  
Data represent mean ± SE. Statistical significance was determined using a student’s t-test test. ** P ≤ 0.01.  
 It was found the border of reactive astrocytes around tumor margins was nearly double 
in the control conditions than in treated conditions.  The 10 mg/kg condition resulted in a 
slightly smaller, but not statistically so, border than the 2 mg/kg condition, indicating a 
slight dose-dependent effect of the treatment.  It should be noted, however, that two weeks 
post-injection with tumor cells has been shown to result in the lowest observed activation 
levels in mouse brains [16], so this effect may be amplified in later stages of tumor growth.   
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 No differences in tumor invasiveness or size were observed in this study, however, due 
to the lack of fluorescent tumor cells, the size and degree of invasion of the tumor before 




 In this study, the effects of human astrocytes on two primary glioblastoma cell lines in 
vitro were characterized.  Though the two cell lines had different responses in terms of 
scale, both cell lines saw an increase in invasiveness in the presence of astrocytes.  From 
these studies, and because the GBM 612 cells are known to be less invasive in vivo [136], 
it was decided that GBM 1A cells were the best model for future experiments.   
 From our preliminary experiments, we determined that astrocyte activation in the 
cancer microenvironment was a promising target for improved glioblastoma therapy, and 
therefore studied the effect of astrocyte activation attenuation on GBM 1A cells in vitro 
and in vivo.  It was found that treatment with either Ibudilast or Laquinimod, two BBB-
permeable drugs currently in clinical trials for other CNS afflictions [127, 131], can 
completely abolish the invasion-promoting effects of astrocytes in a transwell invasion 
assay.  In vivo, it was found that Ibudilast treatment is capable of reducing the size of the 
reactive astrocyte margin around a GBM 1A tumor.  This effect will need to be further 
investigated, and combined activation-attenuating therapy and chemotherapy treatments 
will have to be tested to confirm whether this reduction in astrocyte activation also 
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